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During the last decade, HIV in sub-Saharan Africa has shifted from a fatal disease to a
chronic condition thanks to the expansion of antiretroviral therapy (ART). As a result, the
focus of care has transitioned from survival to quality of life (QoL), and the latter has
become a significant outcome measure during patient follow up. Yet, the determinants of
QoL among HIV patients in western and central Africa are not well known.
The objective of this dissertation was to determine the main factors associated with QoL
among ART-treated HIV adult patients in western and central Africa to ensure healthcare
providers and stakeholders use the most relevant, up-to-date evidence when designing and
implementing interventions that help patients effectively stay in care and remain
asymptomatic.
We first performed a systematic review to synthesize known determinants of QoL in subSaharan Africa. Leveraging the findings of the systematic review, we conducted a crosssectional survey at Espoir Vie Togo (EVT), a patient-oriented community health clinic in
Lomé, Togo, to measure QoL and determine which factors previously identified in the
systematic review were associated with physical and mental domains of QoL in this

population. We also interviewed EVT patients to better understand their life experiences and
potentially uncover novel factors associated with QoL.
The systematic review included 41 observational studies conducted in 14 countries and we
found that QoL was most frequently influenced by sociodemographic factors such as age,
education, gender, employment, social or family support, as reported in nine or more studies;
by clinical factors including mental health and CD4 count; and treatment-related factors such
as treatment duration.
At EVT, the mean (SD) physical health summary (PHS) and mental health summary (MHS)
scores of 147 ART-treated patients were 80.7 (13.9) and 66.7 (11.1), respectively, on a 0-100
scale. Younger age, male gender, food security, the absence of side effects and self-evaluated
“excellent” or “very good” health status were associated with higher PHS scores. Male
gender, a higher level of education, food security, family or social support and self-evaluated
“excellent”, “very good” and “good” health status were associated with higher MHS scores.
Finally, in qualitative interviews with 12 ART-treated EVT patients, patients described good
QoL as being in good health and being physically and mentally functional. Family, social and
community support, the presence of a supporting individual, being on ART and food security
were factors influencing QoL. In this cohort, participants experienced difficulties accepting
their positive status, and often faced perceived or enacted stigma.
The QoL of people living with HIV in western and central Africa is driven by multiple
sociodemographic, clinical and treatment-related factors that have been summarized in this
dissertation. These findings provide stakeholders with valuable evidence to optimize patient
care and management. Future research will focus on pediatric populations and compare

treatment satisfaction between patients receiving care in non-governmental organizations and
in public healthcare facilities.
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BACKGROUND
The HIV/AIDS epidemic has been a major public health challenge in sub-Saharan Africa
for several decades. At its peak in 2005, the number of AIDS-related deaths in sub-Saharan
Africa was 2.4 million, and in 2002, only 50,000 individuals were receiving life-saving
antiretroviral therapy.1,2 However, the launch of the “3 by 5” initiative in 2003 by the Joint
United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization
(WHO) set out to provide 3 million doses of life-saving antiretroviral therapy (ART) to people
living with HIV (PLHIV) in low- and middle-income countries by the end of 2005. 3 That initial
campaign and subsequent ambitious treatment goals led to a significant increase in the number of
HIV positive individuals receiving ART, as well as a decrease in AIDS-related deaths and
consequently, an increase in HIV prevalence.4 In fact, an estimated 15.4 million PLHIV in Africa
were receiving ART in 2017 and 670,000 died from AIDS-related causes, representing a 42%
reduction in AIDS-related mortality from 2004 to 2017 in eastern and southern Africa, and a
24% reduction in western and central Africa.5,6,7
Thus, HIV has shifted from a fatal disease to a chronic condition, and as the life
expectancy of PLHIV continues to increase and becomes similar to that of the general population
in some cases, quality of life (QoL) is emerging as a significant medical outcome in HIV
management.8 WHO defines QoL as “an individual's perception of their position in life in the
context of the culture and value systems in which they live and in relation to their goals,
expectations, standards and concerns.”9 In the context of HIV as a chronic disease, QoL has
become an essential part of follow up assessments. Measuring QoL is key to documenting the
burden of disease, monitoring changes in health, evaluating the efficacy of ART, and analyzing
the cost-effectiveness of ART programs.10 Ultimately, HIV patients with higher QoL scores are
1

more likely to adhere to treatment 11 and thus reduce virologic failure and drug resistance, which
have been shown to be associated with poor adherence to ART. 12

HIV Infection: Epidemiology, Pathogenesis and Treatment
Epidemiology: An estimated 37.9 million people were living with HIV globally in 2018, and 1.7
million were newly infected.13 In low- and middle-income countries, 62% of adults and 54% of
children living with HIV were receiving life-saving ART. 13 The most affected region is the
WHO African region, with 25.7 million PLHIV and approximately two thirds of new HIV
infections globally.13
HIV results from the animal-to-human (zoonotic) transfer of a simian immunodeficiency
virus.15 There are two main types of HIV. HIV type 1 (HIV-1) is the most common type, and it is
classified into four subtypes. Subtype M (major) is responsible for the global HIV epidemic.
Within subtype M, there are nine genetically distinct strains (A, B, C, D, F, G, H, J, K), which
are found in different geographic areas. Nearly fifty percent of all PLHIV globally have strain C,
and it is highly prevalent in eastern and southern Africa.15 The subtypes N (new), O (outlier) and
P are uncommon and restricted to western and central Africa. In Togo, 99.1% of PLHIV have
HIV type 1.58
HIV-2 is mainly prevalent in western Africa. It causes an illness similar to HIV-1 but it is
less infectious, and an HIV-2 infection progresses more slowly and results in fewer deaths. 15,16
The different HIV types found in western and central Africa compared to eastern and southern
Africa thus result in differential risks of transmission, disease progression and quality of life
between these sub-Saharan Africa regions.
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HIV infection is mainly acquired through unprotected sexual intercourse, mother-to-child
transmission, and exposure to infected blood through needles, syringes, or transfusion. 14 The
dominant modes of transmission differ according to geographical regions. In high-income
countries, male-to-male sexual contact is the main mode of transmission whereas vaginal
intercourse and mother-to-child transmission are dominant in developing countries. 15,16
Individuals at increased risk for HIV infection (i.e. key populations) include men who have sex
with men, injection drug users, inmates, sex workers and transgenders. 13
Prevention and treatment are the two current strategies for dealing with the epidemic. Successful
prevention consists of persistent and continuous behavior change interventions, especially in key
populations; a clear understanding of the needs of target populations; and empowering
individuals most at risk.14 There is currently no cure for HIV, but ART effectively controls the
virus and prevents transmission by reducing the viral load to an undetectable level, and it is
increasingly becoming accessible to HIV patients in developing countries.

Pathogenesis: HIV is a retrovirus belonging to the lentivirus genus. 14 Its genome is less than 10
kilobases and although it only encodes 16 viral proteins, it is able to successfully counter the
human immune system.17 Like most viruses, HIV uses host cells to replicate itself and produce
new HIV copies. HIV’s life cycle lasts one to two days, and consists of seven well-documented
stages:14-17
Binding: HIV’s main envelope proteins, glycoprotein (gp)-120 and gp41, bind to CD4 receptors
on the surface of T lymphocytes (also known as T cells) or macrophages, both of which are
HIV’s main target cells. HIV enters the target cell via interactions with CD4 and chemokine
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coreceptors (i.e. CCR5 when the target cell is a macrophage, or CXCR4 when the target cell is a
T cell).
Fusion: HIV’s membrane fuses with the target cell’s membrane and HIV releases its viral RNA,
reverse transcriptase, integrase, and protease into the cell’s cytoplasm.
Reverse transcription. Reverse transcription mediated by viral reverse transcriptase begins and
allows viral RNA to be converted into single-stranded DNA, then into double-stranded DNA
after replication.
Integration: Viral DNA enters the cell’s nucleus and is inserted into the cell’s DNA by viral
integrase.
Replication: The newly formed DNA produces messenger DNA that initiates the synthesis of
HIV proteins, which are building blocks for the formation of more HIV.
Budding: Viral RNA, HIV proteins and components needed to make new viruses gather at the
cell’s membrane and push out of the cell to form virions, immature HIVs that contain all the
components necessary to infect new target cells after maturation.
Maturation: Viral protease cuts HIV proteins into smaller functioning proteins, which combine to
form the viral core of the virus. The virus is now mature and can infect other cells.

Stages of Infection: Without treatment, HIV-infected individuals naturally progress through
three stages of disease, which correspond to the level of viral replication. 18
Stage 1 - Acute HIV infection: Infected individuals may experience a flu-like illness within two
to four weeks after infection. This illness may last for several weeks and it corresponds to the
immune system’s response to the infection. The immune system is not yet producing HIV
antibodies. At this stage, plasma viremia is high, and the risk of transmission is the highest.
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Stage 2 - Clinical latency: HIV infection is chronic or asymptomatic for most patients, and HIV
replicates at low levels. Without treatment, this stage may last a decade or more although some
individuals may progress faster. Individuals may not show signs of illness or have any
symptoms. Patients under ART are virally suppressed and are less likely to transmit the
infection. The end of this phase is characterized by an increasing viral load and a decline in
CD4+ cell count.
Stage 3 - Acquired immunodeficiency syndrome (AIDS): HIV patients are diagnosed with AIDS
when their CD4 count is <=200 cells/mm³ or when they acquire AIDS-defining conditions (also
known as opportunistic illnesses) such as Kaposi sarcoma, Burkitt lymphoma, or recurrent
pneumonia. The immune systems of AIDS patients are highly damaged, and they have high
plasma viremia with high rates of HIV replication. They are also highly infectious and may
experience symptoms such as swollen lymph nodes, weight loss, and weakness. Without
treatment, the life expectancy is three years.

ART and current treatment options: There is currently no cure for HIV, however, antiretroviral
medications are available to help patients live healthier and longer lives. In fact, standard ART, if
taken correctly and regularly, prevents or slows the progression of HIV, and leads to a significant
reduction in HIV morbidity and mortality.14
The therapeutic goals of ART include long-term suppression of HIV replication, immune
function restoration, and improvement in quality of life. 14 Treatment efficacy is measured
through the reduction of opportunistic illnesses, the increase of CD4+ cell count and the decrease
of viral load.14
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HIV patients may experience treatment failure, in which case the combination of antiretroviral
medications is changed according to guidelines.
ART is given daily as a combination of different classes of antiretroviral agents capable of
stopping HIV at different key steps of its life cycle. The initial regimen usually includes three
antiretroviral drugs from at least two different drug classes. 19
There are seven antiretroviral drug classes, classified according to how they interfere with the
virus:
1) nucleoside reverse transcriptase inhibitors (NRTIs) block reverse transcriptase and prevent
the transcription of viral RNA into DNA.19
2) non-nucleoside reverse transcriptase inhibitors (NNRTIs) also block reverse transcriptase.
3) protease inhibitors (PIs) block viral protease and prevent new HIV maturation.
4) fusion inhibitors block HIV from fusing with CD4 cells hence prevent HIV from entering the
cell.
5) CCR5 antagonists block the CCR5 coreceptors on the surface of T cells.
6) post-attachment inhibitors block HIV from binding to CCR5 and CXCR4 coreceptors.
7) integrase strand transfer inhibitors (INSTIs) block viral integrase thus prevent viral DNA
from inserting into the host cell’s DNA.
WHO’s current recommendations are to start HIV-infected individuals on ART as soon as
possible after diagnosis.20 The most current WHO standard guidelines, dated July 2019, are
based on accumulated scientific evidence and experience from diverse HIV programs worldwide.
They recommend starting newly-infected adults and adolescents initiating first-line ART on
dolutegravir (DTG) in combination with two optimized NRTIs (tenofovir [TDF] + lamivudine
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[3TC] (or emtricitabine [FTC])). An alternative first line regimen is efavirenz [EFV] 400 mg in
combination with TDF + 3TC.21
When failing a first-line DTG-based regimen, atazanavir/ritonavir (ATV/r) or
lopinavir/ritonavir (LPV/r)) in combination with two optimized NRTIs (zidovudine [AZT] +
lamivudine [3TC]) is recommended for second-line ART. An alternative second-line regimen is
DTG in combination with AZT + 3TC or with TDF + 3TC (or FTC), if DTG was not taken as a
first-line drug.21
First- and second-line regimens differ for children and neonates, for whom approved DTG
dosing may not be available.

Literature Review
Previous research assessing the QoL of HIV patients treated with ART exists, however,
most studies quantitatively assess QoL scores without searching for potential factors affecting
those scores.22,23 Studies that do investigate the predictors of QoL among PLHIV have been
mostly conducted in high-income countries (in the US, Finland, Spain, Ireland, South Korea, and
Iran) and in eastern and southern Africa (in Rwanda and Uganda). 24-32 In those regions, several
determinants of improved QoL have been identified, including socio-demographic factors (i.e.
male gender, younger age, high socioeconomic status, being employed) and clinical factors (i.e.
lower viral load, higher CD4 cell count).24-32 Those studies also suggest that taking ART and
treatment adherence remain the two key factors associated with improved QoL. 33
There is a lack of evidence on the determinants of QoL in western and central Africa,
where HIV prevalence and incidence rates are significantly lower compared to eastern and
southern Africa, mainly because of historical, religious, and cultural differences, but also because
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of the difference of HIV type associated with the epidemic that results in a differential
progression of the disease.14,34,35 In 2017, of the 25.7 million PLHIV in sub-Saharan Africa, 19.6
million (77%) lived in eastern and southern Africa (out of an estimated population of 597
million)36 while 6.1 million (33%) lived in central and western Africa (estimated population of
436 million).36 Moreover, there were 800,000 new HIV infections in eastern and southern Africa,
compared to 370,000 in western and central Africa.35 Thus, generalizing findings from studies
conducted in eastern and southern Africa to western and central Africa may not be appropriate,
and it is preferable to assess trends and patterns in each region separately in order to better
interpret and understand research findings.
Because of the aforementioned historical, cultural and religious particularities, as well as
specificities of the epidemic and the paucity of research, there is a need for a comprehensive
assessment of factors affecting QoL in central and west African HIV patients. 34 A previous
cross-sectional study evaluated QoL and depression in 200 ART-treated Senegalese patients but
did not search for an association.37 Another cross-sectional study investigating QoL among 158
HIV-positive patients in rural Ghana found that being a female, sexually active, asymptomatic
and treated with ART were associated with higher QoL scores. 38 Further, a cross-sectional study
of 491 Nigerian PLHIV found that being ≥40 years old was associated with the environment and
spirituality domains of QoL, being married with social relationship, self-reporting a “good” or
“very good” health status with all domains, a CD4 cell count ≥350 cells/mm 3 with the physical,
psychological and level of independence domains, and being on ART for more than 18 months
with the psychological, level of independence and spirituality domains of QoL. Unfortunately,
this study did not adjust for confounders and results should be interpreted with caution. 39
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What these studies have in common is that they used previous literature as the source of
risk factors for their investigation. Although it is common practice in epidemiological research,
this results in the same demographic and clinical variables being repeatedly assessed, and this
does not allow new factors to be investigated. A systematic review can be used to synthesize and
systematically identify risk or protective factors from diverse and scattered publications, then
analyze them comprehensively. This method will help detect under-investigated yet significant
factors associated with QoL.
In 2014, Degroote conducted a literature review to identify determinants of QoL in
PLHIV in high-income countries and although a few studies drew conflicting results, the author
reported that overall, certain socio-demographic characteristics (i.e. male gender, younger age, a
stable relationship, employment, and higher education) were associated with higher QoL. 40
Moreover, clinical factors such as better virological status, starting ART at CD4 <200 cells/µl,
early HIV stage, and the absence of HIV-related symptoms or comorbities were also associated
with higher QoL. Finally, psychological factors including depression, anxiety, HIV status
disclosure and stigma were negatively associated with QoL whereas social support was
positively associated. Although Degroote identified several factors associated with QoL, their
review may not be generalizable to sub-Saharan Africa, which is fundamentally different from
high-income countries in many aspects, notably in the social and molecular epidemiology of the
epidemic.41
Two systematic reviews geographically restricted to sub-Saharan Africa analyzed QoL
among PLHIV receiving ART. One (Beard 2009) assessed the effect of ART on QoL, mental
health, labor productivity, and economic wellbeing. 42 This review found ART to be associated
with significant improvements in daily function, and physical, emotional and mental health
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domains of QoL. Concerning work-related outcomes, performance improved, and absenteeism
decreased in patients receiving ART. Unfortunately, factors associated QoL other than ART
were not investigated. The other review (Robberstad & Olsen 2010) first reported a synthesis of
eight studies quantitatively assessing QoL in PLHIV for economic evaluations purposes, then
described the findings of a focus group of HIV clinicians on EuroQol-5D (EQ-5D), a QoL
instrument measure, and its use in low-income settings. 43 The authors did not seek to identify
factors associated with QoL.
Hence, a systematic review summarizing risk or protective factors associated with QoL
among sub-Saharan African populations would address the current gap in knowledge.
Subsequently determining which of these factors is associated with QoL would help improve
patient wellbeing, and more importantly improve ART adherence, given that treatment
adherence is a key factor associated with higher QoL, as previously mentioned. 33. Given the
current importance of QoL in HIV management, healthcare professionals can benefit from
additional insight on the risk factors causing HIV patients to fall out of care. The consequences
of loss to follow up due to poor QoL among patients who started ART are detrimental, not only
for the patients themselves but also in terms of potential spread of the infection and in the
success of ART programs in sub-Saharan Africa.44
In addition to investigating the relationship between risk or protective factors and QoL,
this dissertation attempted to further examine the qualitative aspect of QoL research among
PLHIV in western and central Africa. Several qualitative studies have been conducted in this
region to better understand perceptions of QoL among PLHIV, and we believed that including a
qualitative component to this dissertation may contribute to gain additional knowledge on factors
influencing QoL in the region. In a qualitative study conducted in Uganda, Mutabazi-Mwesigire

10

(2014) interviewed HIV patients and asked them to define QoL, and what their perception of
QoL was.45 The author reported that their description was similar to that of the World Health
Organization. More interestingly, her research allowed for the discovery of indicators of QoL as
perceived by HIV patients, such as happiness, food availability, shelter or availability of money.
A similar approach can be undertaken in our dissertation to allow participants to discuss QoL
issues that may affect their lives, and potentially lead to the discovery of indicators of QoL in the
social and cultural context of western and central Africa.

Public Health Significance
The management of HIV as a chronic disease requires lifelong therapy and sustained
care, mainly to ensure continued adherence to ART and rapid adjustments as treatment failure
arises.46 This requires well-honed and well-resourced healthcare delivery systems, which are
often lacking in sub-Saharan Africa. However, the lack of efficient healthcare systems at the
national level can be balanced by excellent patient care at the community clinic level. Knowing
that over 1.1 million individuals in sub-Saharan Africa were newly infected in 2017, treating
those individuals early and retaining them in care would contribute to their achievement of viral
suppression, which is one of the key steps of UNAIDS’s 90-90-90 treatment target to end the
AIDS epidemic by 2020 (i.e. by 2020, 90% of PLHIV will know their HIV status, 90% of those
infected will receive sustained ART and 90% of those receiving ART will have viral
suppression).35,47 Retaining patients in care is a major challenge in sub-Saharan Africa, and one
significant way to overcome it is to ensure patients maintain a high QoL as they cope with their
disease. It is therefore crucial to determine the major modifiable factors associated with QoL to
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allow healthcare providers and stakeholders to act upon them and ensure patients effectively stay
in care, remain asymptomatic and do not transmit the infection.

Specific Aims
The following aims will help determine the main factors associated with QoL in ARTtreated PLHIV in west and central Africa.
Aim 1: Conduct a systematic review to identify the main factors associated with
standardized quality of life measures in ART-treated HIV adult patients in sub-Saharan Africa.
Aim 2a: Measure the quality of life of HIV patients receiving long-term ART in a
community health clinic in Togo.
Aim 2b: Assess the association between main socioeconomic, clinical and treatmentrelated factors identified in the systematic review and physical and mental domains of QoL in
patients of a community health clinic in Togo, after adjusting for demographic variables.
Aims 3: Identify indicators of quality of life as described by ART-treated HIV patients of
a community health clinic in Togo during qualitative interviews.
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METHODS
Aim 1.
Study Design
The first part of this dissertation was a systematic review with the aim to identify key risk
or protective factors associated with QoL in sub-Saharan Africa.
Prior Systematic Reviews and Registration
Prior systematic reviews on this topic were searched for, first on the Texas Medical
Center library website using the following search term: (hiv OR aids) AND (“Quality of Life”
OR QOL OR HRQoL) AND (sub-Saharan Africa) AND (“systematic review” OR “metaanalysis”), second on Medline, by combining the following search terms: (hiv OR human
immunodeficiency virus OR aids OR acquired immunodeficiency syndrome), (quality of life OR
health-related quality of life OR QOL OR HRQoL), exp “Africa South of the Sahara”/ and
(systematic review OR meta-analysis), and finally on PubMed using search terms similar to
Medline’s.
An additional search was conducted on PROSPERO, the international database for
registering systematic reviews. To ensure the most comprehensive and complete search possible,
only “HIV” was used for the search. 33 HIV-related reviews were found. We reviewed them
individually to assess whether a review of the association between risk or protective factors and
QoL in HIV patients was already registered. No previous review matching our methodology was
found therefore we registered our proposed systematic review (PROSPERO CRD42019136202).
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Participants
Study participants for the systematic review were sub-Saharan HIV-positive individuals
aged 18 years or older who were taking antiretroviral therapy. Following the PICOTS principle,
participants were “HIV-positive individuals aged 18 years or older”, intervention was
“antiretroviral therapy”, comparator was “any” or “none”, outcome was “any quality of life
assessment obtained using a standardized questionnaire or instrument (such as World Health
Organization Quality of Life-HIV [WHOQOL-HIV], Medical Outcomes Study HIV Health
Survey [MOS-HIV], EQ-5D, 36-Item Short Form Survey [SF-36], etc…), including an adjusted
analysis assessing an association between risk or protective factors and QoL”, time was “any”,
setting was “sub-Saharan Africa” and study design was “randomized or non-randomized
controlled trial (any phase), observational studies (comparative or non-comparative), and pooled
analyses”.
Search Strategy
Our systematic review was conducted following Methodological Expectations for
Cochrane Intervention Reviews (MECIR) standards.48 A systematic search from inception to
May 2019 was conducted on Medline, PubMed, Embase and PsycINFO to identify studies for
inclusion. In addition, non-databases sources, including GreyNet, Grey Literature Report and
BIOSIS Previews, were searched for grey literature such as meeting abstracts, posters and
unpublished articles.
Our search strategy was tailored for each database. It combined HIV, quality of life and
sub-Saharan Africa terms as shown in Appendix A for Ovid Medline, Appendix B for PubMed,
Appendix C for Embase and Appendix D for PsycINFO.
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Study Selection
Two independent screeners (Oubote Sangbana, Peter Elyanu) performed a title/abstract
screening in order to exclude studies not meeting the pre-determined criteria.
Exclusion reasons during screening were age <18 years old, not HIV-positive, not in subSaharan Africa, does not include ART, does not include QoL outcomes, does not include a
standardized QoL instrument, not an original study, not a clinical study, animal study, or in vitro
study. Cohen’s Kappa was calculated to assess interrater reliability, and areas of disagreement
between the two screeners was resolved by consensus. Following the title/abstract screening
phase, a full text review phase was performed in order to select studies reporting outcomes of
interest. The primary outcome was a QoL assessment from a previously validated questionnaire
(eg. WHOQOL, MOS-HIV, EQ-5D, SF-36). The secondary outcome was any risk or protective
factor reported in the study to be associated (p<0.05) with improved or reduced QoL, after
adjustment.
Data Collection
A brief data collection form was created after selecting studies meeting the inclusion
criteria. One reviewer (OS) extracted all data of interest listed in the form using an excel
spreadsheet. A second reviewer (Akira Look) reviewed the extracted data for errors.
Disagreements were resolved by consensus. Per Cochrane recommendations, items to collect
from each selected study included data related to the source, eligibility, methods, participants,
interventions, outcomes, and key findings.49 Most importantly, it included the factors associated
with improved or reduced QoL. A risk or protective factor was selected and retained for the
second part of this dissertation if was statistically significantly associated (p<0.05) with overall
QoL or domains of QoL, after adjustment, in three or more studies.
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An evidence table was created to summarize and present characteristics and key findings from
each study. It included the author’s name, country, study dates, sample description, QoL
instrument, risk or protective factors, and key findings.
Preliminary rapid scoping review
To assess the feasibility of our systematic review, we conducted a preliminary rapid
scoping review, and 12 studies meeting our inclusion criteria were identified (data not shown).
Potentially extractable risk or protective factors affecting QoL are shown in table 1.
Table 1. Potential variables of interest from a preliminary focused literature review.
Variable

Format
Demographics
Male, Female
Continuous (years) or Categorical
None, Primary, Secondary or more
Student, Employed, Unemployed, Other
Single, Married or Partner, Separated/Divorced,
Widowed

Gender
Age
Education Level
Employment Status
Marital Status

Health-Related
Duration of treatment
Regimen
Treatment adherence
Social Support
Alcohol Use
Drug Use
Sexually Active
Self-Perceived as Healthy
Time Since HIV

Continuous (months) or Categorical
1st Line, 2nd Line, >=3rd Line
Yes, No
Yes, No
Yes, No
Yes, No
Yes, No
Yes, No
Continuous (months)
Clinical

Viral Load
CD4+ count
HIV/TB co-infection
Treatment-related adverse events
HIV Serostatus

Continuous (copies/mL) or Categorical
cells/mm3
Yes, No
Yes, No
Symptomatic, Asymptomatic, AIDS
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Risk of Bias
The risk of bias for each included study was assessed using National Institutes of Health
(NIH)’s 14-item quality assessment tool for observational cohort and cross-sectional studies. 50
The 14 questions were:
1. Was the research question or objective in this paper clearly stated?
2. Was the study population clearly specified and defined?
3. Was the participation rate of eligible persons at least 50%?
4. Were all the subjects selected or recruited from the same or similar populations (including the
same time period)? Were inclusion and exclusion criteria for being in the study prespecified and
applied uniformly to all participants?
5. Was a sample size justification, power description, or variance and effect estimates provided?
6. For the analyses in this paper, were the exposure(s) of interest measured prior to the
outcome(s) being measured?
7. Was the timeframe sufficient so that one could reasonably expect to see an association
between exposure and outcome if it existed?
8. For exposures that can vary in amount or level, did the study examine different levels of the
exposure as related to the outcome (e.g., categories of exposure, or exposure measured as
continuous variable)?
9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and
implemented consistently across all study participants?
10. Was the exposure(s) assessed more than once over time?
11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and
implemented consistently across all study participants?
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12. Were the outcome assessors blinded to the exposure status of participants?
13. Was loss to follow-up after baseline 20% or less?
14. Were key potential confounding variables measured and adjusted statistically for their impact
on the relationship between exposure(s) and outcome(s)?
For each item, possible choices were “yes”, “no” or “other” (i.e. “cannot determine”, “not
applicable” or “not reported”).

After completion of the systematic review, several demographic, socioeconomic, clinical
and treatment-related factors associated with QoL in ART-treated sub-Saharan HIV adult
patients were identified, and the second part of the dissertation was initiated.
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Aim 2.
Study Design
The second part of this dissertation was a cross-sectional study with the aim to measure
the QoL of HIV patients receiving long term-ART in a community health clinic in Togo (Aim
2a), and assess the association between key risk and protective factors and QoL (Aim 2b).
Study Setting
The study was conducted at Espoir Vie Togo (EVT), a community health clinic in Lomé,
Togo. EVT is a non-governmental organization created in 1995 and its mission is to treat and
provide social support to PLHIV in Togo. A team of 79 healthcare providers (physicians,
medical assistants, nurses, midwives, etc.) at three locations in the country (Lomé [Togo’s
capital], Aného, Sokodé) manages about 3,500 PLHIV, and this number has been steadily
increasing over the last two decades.51
Sampling Strategy
The study’s target population was western and central African PLHIV.
Lomé university hospital, Centre Hospitalier Universitaire (CHU) Sylvanus Olympio, refers
patients to EVT, which accepts all referred patients without exclusion. Patients come from
various socioeconomic backgrounds and they are representative of urban HIV patients in west
and central Africa.
Study Subjects
Participants were consecutive men and women HIV patients who visited the outpatient
community clinic in July and August 2019. Participants were given a 500 CFA (~ US $0.85)
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token as reimbursement for travel expenses (Appendix L). Eligibility criteria were as follows:
>=18 years, a confirmed HIV diagnosis and currently taking ART.
Ethical Approval
Ethical approval was obtained from the Comité de Bioéthique pour la Recherche en Santé
(031/2019/CBRS) in Togo (Appendix J), and from the University of Texas Health Science
Center at Houston’s Committee for the Protection of Human Subjects (HSC-SPH-19-0357)
(Appendix K). All participants provided verbal informed consent.
Sample Size Calculation
We estimated the sample size based on a fixed model and R-squared increase for linear
multiple regression. We assumed a medium population effect size (i.e. 0.15; corroborated by a
previous study conducted in China)53, a power of 80%, a significance level of 5%, and 15
predictors. Using G*Power software Version 3.1.9.4, a sample size of 140 was generated. 52
Data Collection
Two study investigators (Oubote Sangbana [primary investigator]; Jean Marie AtsouAlley [secondary investigator and EVT’s clinical psychologist and patient coordinator]) collected
data before or at the end of patients’ doctor visits. The clinic’s primary physician (Nina Dapam)
asked patients if they were interested in participating in the study and, in case of a positive
response, they were directed towards the study investigator. The investigator explained the
objective of the study following a verbal script (Appendix E), then sought verbal informed
consent. If verbal informed consent was obtained, data collection proceeded, in two phases.
First, basic demographic and socioeconomic characteristics were collected from the patient’s
medical records (Table 2, Appendix F). Questions related to the risk or protective factors
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identified during the systematic review were also collected directly by asking patients. Overall,
the characteristics collected were: gender, age, education level, employment, marital status, body
mass index (BMI), HIV status disclosure, social or family support, alcohol use, food insecurity,
serostatus, CD4 count, viral load, treatment duration, ART regimen, line of treatment, adherence,
and side effects. Second, participants were administered the French version of the MOS-HIV
survey (Appendix G,H). Survey questions were digitalized beforehand: rather than being in a
paper form, the questionnaire was entered on the Qualtrics application on an Apple iPad and the
investigators read the questions to the patients and recorded the answers directly on the Qualtrics
application.
Table 2. Collectable data from EVT patients’ visit cards.
Variables
Page 1
Temperature

Page 2
Opportunistic Infections (Type)

Pulse
Blood Pressure
Weight
Height
Age †
Status (Well, Can Move, In Bed)

Opportunistic Infections (Treatment)
Side Effects
TB Test Requested
Suspected TB (Yes, No)
Confirmed TB (Yes, No)
Date TB Confirmed

Pregnant
CD4+ count | Date Collected
Viral Load
ART Status (Start, Continued, Change, Stop)
Reason for Changing ART a
Reason for 2nd Line ART

TB Treatment
Other Concomitant Diseases
Adherence to ART (Yes, No) !
Number of Doses Omitted in the Last Week
Hemoglobin Level *
ALT or SGPT b

Reason for Stopping ART
ART (Original 1st Line, Switched 1st Line, 2nd Line
Concomitant Medication
Duration of Treatment
Treated for Opportunistic Infections
Co-trimoxazole Prophylaxis

Creatinine
Blood Sugar
Triglycerides
Cholesterol
Amylase
Lipase
CPK

a

b

Antiretroviral Therapy; Alanine transaminase or serum glutamic-pyruvic transaminase; * Bolded variables indicate the latest
data available; † Underlined variables indicate variables of interest; ! Defined as attending doctor appointment.
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MOS-HIV
The survey administered was the MOS-HIV (Appendix G,H). It is a previously validated
instrument that produces an overall QOL profile specific to HIV patients. It assesses health
transition and 10 dimensions of QoL: general health perceptions, pain, physical functioning, role
functioning, social functioning, energy/fatigue, mental health, health distress, cognitive
functioning, quality of life (Figure 1).54,55

MOS-HIV
Dimensions
Social
Functioning

Pain
Cognitive
Functioning

Mental Health

Health
Distress

General Health
Perceptions

Physical
Functioning

Quality
of Life

Role
Functioning

Energy /
Fatigue

Figure 1. Dimensions of the MOS-HIV health survey.

The MOS-HIV is a disease-specific instrument and contains 35 items. Items are scaled on
a 3, 5 and 6-point Likert scale without weighting of items. After linear transformation, the scores
range from 0 to 100, where higher scores indicate better QOL. Guidelines for calculating the
scores for each dimension are provided with the survey upon request.
The French version of the MOS-HIV and permission to use the questionnaire were obtained by
submitting a request on the dedicated website supported by Mapi Research Trust. 56
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Data Analysis
Aim 2a: MOS-HIV Scores
Per scoring guidelines, 11 of the 35 items were recoded to reverse their directionality.
Items composing each scale were summed up to compute raw scores, as shown in Table 3. Raw
scores were transformed linearly to a 0-100 scale according to the following formula:
[(maxnew – minnew) / (maxold – minold)] x [(v – maxold) + maxnew]
where maxnew and minnew are 0 and 100, respectively, minold and minold are the item’s minimum
and maximum boundaries, and v is the observed value.
Then, a physical health summary (PHS) score and a mental health summary (MHS) score were
computed using a factor analysis with oblique rotation, as described by Revicki (1998). 57 All
coding and computation were performed using SAS software, Version 9.4, SAS Institute Inc. 59
Table 3. Equations to compute MOS-HIV dimensions scores.
Domain
General health perceptions

Equation*
Q1 + Q11a + Q11b + Q11c + Q11d

Physical functioning

Q4a + Q4b + Q4c + Q4d + Q4e + Q4f

Role functioning
Social functioning
Cognitive functioning
Pain
Mental health

Q5 + Q6
Q7
Q10a + Q10b + Q10c + Q10d
Q2 + Q3
Q8a + Q8b + Q8c + Q8d + Q8e

Energy/Fatigue

Q9a + Q9b + Q9c + Q9d

Health distress

Q9e + Q9f + Q9g + Q9h

Quality of life

Q12

Health transition

Q13

*Raw scores are subsequently linearly transformed to a 0-100 scale
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Aim 2b: Multiple Linear Regression
Two multiple linear regression analyses, one with PHS as the dependent variable, and the
other with MHS as the dependent variable, were fitted to determine the factors associated with
QoL. The independent variables were gender, age, education level, employment, marital status,
BMI, HIV status disclosure, social or family support, alcohol use, food insecurity, serostatus,
viral load, treatment duration, ART regimen, line of treatment, adherence, self-evaluated health
status and side effects. All analyses were performed using SAS software Version 9.4. 59
Data Preparation. After data cleaning, independent variables were inspected for
multicollinearity using correlation matrices. In case of highly correlated variables, one variable
was dropped.
Preliminary Models. For each health summary score (PHS and MHS), a preliminary model was
fitted using the domain score (continuous) as the dependent variable and risk or protective
factors (continuous, binary or categorical) as the independent variables.
Diagnostics. All linear regression assumptions were assessed, and remedial measures such as
variable transformation were applied in case of assumptions’ violations.
Model Selection. Stepwise model selection was performed to determine the subset of variables
best defining the relationship between the independent variables and the specific health summary
score under investigation.
Model Validation. The most parsimonious model selected during the model selection phase was
validated using the data splitting approach (or cross-validation). The dataset was randomly split
into two equal sets. One set was used as the model-building (training) set. The other set was used
as the validation set. Estimated β coefficients obtained in the training set were used to predict
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estimates in the validation set, and the agreement between estimated β coefficients and standard
errors between the two sets was assessed.
Potential influential points were then analyzed in the model-building set.

Results from the model selection were reported in a table showing the dependent variable
(PHS and MHS), the independent variables selected during model selection, the β coefficients,
the 95% confidence intervals and the p-values. The directionality of variables statistically
significantly associated with QoL after adjustment was recorded.
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Aim 3.
Study Design
The third part of this dissertation was a qualitative assessment of ART-treated HIV
patients with the aim to understand patients’ definitions of QoL, identify and gain additional
knowledge on underlying and undiscovered indicators of quality of life, and better understand
the life experiences of HIV patients in this population.
Data Collection
Every day, one patient visiting the outpatient clinic was asked to participate in the
qualitative assessment, in addition to being administered the MOS-HIV survey, before or after
the doctor visit. Face-to-face individual interviews took place before administering the survey to
ensure participants’ responses were not limited by the constructs and dimensions used in the
survey. Participants were given a 500 CFA (~ US $0.85) token as reimbursement for travel
expenses (Appendix L). Eligibility criteria to be interviewed for the qualitative assessment were
being 18 years or older, having a confirmed HIV diagnosis and currently taking ART more than
six months.
The primary investigator (OS), assisted by a clinical psychologist with qualitative
interview experience (JMAE), conducted the interviews, which were held in a private
consultation room to ensure patient’s confidentiality. All interviews were held in French, the
official language and first language of most participants. No time limit was predetermined but
the interviews lasted approximately 15 minutes. The interview was recorded on a digital audio
recorder, and written notes were also taken by the study investigator during the discussion. No
participant refused to be recorded. The discussion felt relatively informal and this allowed
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participants to engage in a conversation rather than a question-answer session. This approach
also encouraged participants to give honest answers.
Based on an interview guide specifically developed for this study, a series of open-ended
questions were asked:
1. a) What is a good quality of life for you?
b) How is that different or similar to what others experience?
2. a) How have your ideas of a good quality of life changed after HIV?
b) What was it before and how has that changed over time and in relation to what?
3. Are there things or people that put your quality of life at risk? Please tell me about them.
The questions were open-ended, and the investigator discussed risk and protective factors
more in depth as deemed necessary. The overall aim was for participants to share their definition
of QoL and describe the factors improving or impeding their quality of life in the context of HIV.
Ethical Approval
Ethical approval was obtained from the Comité de Bioéthique pour la Recherche en Santé
(031/2019/CBRS) in Togo (Appendix J), and from the University of Texas Health Science
Center at Houston’s Committee for the Protection of Human Subjects (HSC-SPH-19-0357)
(Appendix K). All participants provided verbal informed consent.
Data Analysis
Audio recordings were fully transcribed and translated from French to English. Handwritten notes were typed and translated in English. Data analysis was performed using
OpenCode version 4.0.60 Data were analyzed following a thematic analysis. Transcripts were
read multiple times to become familiar with the content. The primary investigator (HS) used an
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open coding approach to capture the participants’ life experience and perception of QoL. After
coding several transcripts, a set of codes were defined and subsequently used for similar
recurring concepts. Additional codes were incorporated into the analytical framework as they
were identified in subsequent transcripts. Several themes emerged and were examined at the
latent level: the investigator sought to detect underlying ideas and concepts by analyzing
patients’ words beyond what was said verbatim during the interviews. All themes were reviewed
by an experience researcher who did not take part in the interviews (SM)
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Human Subjects, Animal Subjects, or Safety Considerations
This dissertation included the use of the MOS-HIV, a previously validated questionnaire,
for the assessment of QoL in human subjects. The latter consisted of HIV patients treated at
Espoir Vie Togo, a community clinic in Lomé, Togo. Data collection took place during a onemonth period and involved 147 patients. Each patient was assessed only once, and the survey
was completed in approximately 10 minutes. Participants were given a 500 CFA (~ US $0.85)
token as reimbursement for travel expenses. Verbal informed consent was sought to access
patients’ medical records in order to collect demographic data and the most recent clinical data
prior to the assessment. Patients were clearly informed of their right to not participate in the
study and of their ability to withdraw from the study at any time if they chose to do so. Proper
ethical approvals were requested from UTHealth’s Committee for the Protection of Human
Subjects (CPHS) and the Togolese Comité de Bioéthique pour la Recherche en Santé. A letter of
support was obtained from Espoir Vie Togo since it does not have an ethics committee
(Appendix I).
The main risks incurred by study participants were breach of confidentiality and loss of
privacy since the investigators (Oubote Sangbana [primary investigator]; Jean Marie Atsou-Alley
[secondary investigator and EVT’s clinical psychologist and patient coordinator]) accessed
private information included in patients’ medical records. This risk was mitigated by accessing
the record in front of the patient, only for a brief period and only to record the few demographic
and clinical variables necessary for the completion of the study. No personal identifying
information was collected. Moreover, the primary investigator completed Collaborative
Institutional Training Initiative (CITI) training for the protection of human subjects and ethical
conduct and followed all standard practices to maintain patient privacy. The secondary
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investigator, who is in contact daily with the clinic’s patients, was previously trained on-site by
local administrators to maintain patient privacy and protect human subjects.
The Apple iPad used for the questionnaire assessment was password-protected and only the two
study investigators knew the password. It was not connected to the internet. All data collected on
the iPad were deleted once transferred to the primary investigator’s password-protected laptop
computer for analysis.
In summary, the benefits of the findings of this study exceeded the risk incurred, and the
study protocol was consistent with sound research procedures and did not expose patients to
unnecessary risks.
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Abstract
As HIV evolved from a fatal infection to a chronic disease, quality of life (QoL) has
emerged as a significant medical outcome. The objective of this systematic literature review was
to identify key risk or protective factors associated with QoL in sub-Saharan Africa. We
searched Medline, PubMed, Embase, and PsycINFO from inception to May 2019 and GreyNet
and International AIDS Conference archives for original publications. Two screeners
independently reviewed titles and abstracts, and full texts of relevant articles for factors
statistically associated with QoL. In all, 41 observational studies with multivariate analyses
conducted in 14 countries met eligibility criteria. As reported in 9 or more studies, higher QoL
was associated with sociodemographic factors: younger age, employment, higher education
level, male gender, and social or family support; and a treatment-related factor: longer treatment
duration. Lower QoL was associated with clinical factors: mental health and lower CD4 count.
This review summarizes the evidence in the literature and highlights key factors affecting the
QoL and well-being of ART-treated people living with HIV in sub-Saharan Africa.
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Introduction
In the last decade, the scale-up of antiretroviral therapy (ART) has changed the course of
the HIV/AIDS epidemic in sub-Saharan Africa, with an estimated 40% reduction in HIV-related
mortality from 2010 to 2018 (1). Although there were an estimated 470,000 HIV-related deaths
in 2018, HIV has shifted from a fatal disease to a chronic condition and the HIV care continuum
and management approach have evolved to meet the demands of this new paradigm (2). As a
result, quality of life (QoL) has emerged as a significant outcome during follow-up for those
receiving ART (3,4). Measuring QoL is key to documenting the burden of disease, monitoring
changes in health, evaluating the efficacy of ART, and analyzing the cost-effectiveness of ART
programs (5). Moreover, patients who maintain a good QoL as they cope with their disease are
more likely to adhere to treatment and thus reduce virologic failure and drug resistance (6,7). It is
therefore crucial to determine the main factors associated with QoL to ensure healthcare
providers use the most relevant, up-to-date evidence in implementing interventions that help
patients to effectively stay in care and remain asymptomatic.
An increased research interest in the determinants of QoL has been observed in low-income
countries in the last decade, and yet, a synthesis of recent findings on the topic has to be
published. This gap is especially important for sub-Saharan Africa, where the course of the
disease is unique due to its historical, religious, and cultural singularities. The profile of the
epidemic also differs from other regions because of the diverse distribution and prevalence of
HIV subtypes across countries in sub-Saharan Africa (8,9,10). There is a need for a regionspecific review to capture this part of the African experience and provide a comprehensive
overview of the available data on risk and protective factors influencing QoL in this region. The
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objective of this review was to identify and summarize the factors associated with QoL among
sub-Saharan adult HIV patients treated with antiretroviral therapy.
Methods
This systematic review was conducted following Methodological Expectations for
Cochrane Intervention Reviews (MECIR) standards and reported according to Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (11,12). The
protocol was registered with the international prospective register of systematic reviews
(PROSPERO CRD42019136202) and can be accessed on PROSPERO’s website.
Inclusion criteria
Inclusion criteria followed a pre-specified PICOTS framework (13). The population was
HIV patients aged 18 years or older under treatment with ART or highly active antiretroviral
therapy (HAART) for any duration; independent variables were any sociodemographic, clinical,
behavioral or treatment-related variables, the outcome of interest was any quality of life
assessment obtained using a standardized questionnaire or instrument (e.g. World Health
Organization Quality of Life-HIV [WHOQOL-HIV], Medical Outcomes Study HIV Health
Survey [MOS-HIV], EuroQol-5D [EQ-5D]). Any publication date was accepted, the setting was
a sub-Saharan country, and all quantitative study designs were considered. In addition, studies
had to include an adjusted analysis assessing an association between QoL and risk or protective
factors. There were no language restrictions.
Search strategy
We searched Medline, PubMed, Embase, and PsycINFO from inception to May 2019 to
identify studies investigating the QoL of ART-treated sub-Saharan African HIV patients. Non34

database sources including GreyNet and the international AIDS conference archives were
searched for abstracts, presentations and unpublished articles. The following concepts were
tailored for each database: HIV/AIDS, ART, quality of life and sub-Saharan Africa. The search
query for Medline is available in the supplementary material (Supplementary Table 1), and
others from HS. All citations found through searches were stored on RefWorks (ProQuest,
Michigan, USA). Search results were tracked and managed using an Excel workbook designed
for this purpose (14).
Study Selection
Two authors (HS, PE) independently screened all titles/abstracts. Prior to screening, the
authors reviewed a random sample of 76 titles/abstracts to assess interrater reliability (Cohen's
kappa [standard error] = 0.86 [0.076]) (15). Disagreements were resolved by consensus.
Subsequently, full texts of relevant studies were reviewed independently (HS, AL) and
disagreements were also resolved by consensus.

Data collection
One reviewer (HS) used a standardized data collection form to extract the following data
items from each included study: author’s name, publication year, country, study design and
duration, sample size, population characteristics, ART regimen, QoL instrument, and risk or
protective factors whose association with improved or reduced QoL was investigated through an
adjusted statistical analysis. We collected all statistically significantly associated (p<0.05)
variables. A second reviewer (AL) reviewed the extracted data for errors.
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Risk of bias assessment
One reviewer (HS) assessed the likelihood of bias in each included article using National
Institutes of Health’s 14-item quality assessment tool for observational cohort and crosssectional studies (16). For each item, possible choices were “yes”, “no” or “other” (i.e. “cannot
determine”, “not applicable” or “not reported”). According to the tool, studies were categorized
as “good”, “fair” or “poor”, and a second reviewer (AL) reviewed all ratings. Disagreements
were resolved by consensus.
Results
From all sources, 795 unduplicated records were identified, and 41 studies met inclusion
criteria (Figure 1). Main reasons for exclusion were: ART was not the intervention of interest,
risk factors were not investigated, and analyses were not adjusted.
Description of studies
Included studies were published from 2007 to 2019 and conducted in 14 sub-Saharan
African countries. Ethiopia (k= 10), Uganda (k= 7), Nigeria (k= 5) and South Africa (k= 5) were
the most frequent countries of research. All studies were observational, including 27 (66%)
cross-sectional surveys. The total sample size was 18,055. Ten different QoL instruments were
used, including WHOQOL, MOS-HIV, 36-Item Short Form Survey (SF-36), EQ-5D, and the
HIV/AIDS-Targeted Quality of Life Instrument (HAT-QoL). Moreover, nine studies reported
associations with QoL as an overall score while 32 studies assessed associations with specific
domains of QoL. Study characteristics and main findings are shown in the supplementary
material (Supplementary Table 2).
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Identification

Records identified through
database searching
(k = 1567)

Additional records identified
through grey literature
(k = 3)

Included

Eligibility

Screening

Records after duplicates removed
(k = 795)

Records screened
(k = 795)

Full-text articles assessed
for eligibility
(k = 96)

Studies included in
qualitative synthesis
(k = 41)

Records excluded
(k = 699)

Full-text articles excluded
(n = 55)
3 No std. QoL instrument
8 No risk factors
1 Wrong population
1 Not in sub-Saharan Africa
20 Wrong intervention
10 No adjusted analysis
4 Secondary analyses
1 FT unavailable
7 Other

Figure 2. PRISMA flow diagram of the selection process of relevant articles
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Quality of individual studies
Twenty-seven studies demonstrated an overall strong internal validity and were rated as
good. These studies were conducted based on a robust methodology, and no significant flaws in
the conduct of the study or the statistical analyses were identified. Twelve studies were rated as
fair, as they presented one or several weaknesses increasing the risk of bias such as the method
of selection of participants or confounding. Lastly, six studies overall were rated as poor because
of a high risk of bias, notably in the statistical analyses or in the methodology related to the
measure of the risk factors or the measurement of QoL.
Heterogeneity across studies
When assessing heterogeneity across studies, we found several differences in the
methods. Ten different instruments were used across studies to measure QoL and this diversity
may impact the overall joint evidence since QoL domains vary across instruments. For example,
MOS-HIV is always summarized into two domains (physical and mental health summaries) for
analyses purposes, while WHOQOL-HIV is more comprehensive and measures six domains
(physical, psychological, level of independence, social relationships, environment,
spirituality/religion/personal beliefs). Lastly, both generic and disease-specific instruments were
used across studies. On one hand, generic instruments assess QoL changes resulting from overall
clinical features and they are designed for use across different patient populations. On the other
hand, disease-specific instruments are generally more sensitive and better designed to measure
QoL variations related to specific disease characteristics (17).
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Table 4. Factors associated with quality of life identified in 41 studies.
Characteristic

Number of studies reporting an
association with quality of life*

Sociodemographic Factors
Age
Employment/Income/SES
Education Level
Gender
Social/Family Support
Marital Status
Region/Residence (Urban/Rural)/Type of clinic
Food security/Diet diversity
Knowledge of partner's HIV status/Disclosure of status
High risk sexual behavior/Sexual activity/Number of
partners
BMI/Body fat redistribution/Abdominal obesity
Stigma
Clinical Factors
Depression/Psychological distress/Mental
disorder/PTSD
CD4 Count
WHO Stage
Symptoms
Health Status/Illness (self-evaluated)/Hospitalization
Baseline QoL/Domain of QoL
Tuberculosis
Viral Load/Plasma HIV copies
NCD/Chronic disease/Comorbidity
Treatment-Related Factors
Treatment Duration/Follow up time
ART/Type of regimen
Adherence
Side Effects/Toxicity

16
14
10
10
9
7
6
6
4
4
3
3
13
9
7
5
4
4
3
3
3
11
4
4
3

*Overall quality of life or domains of quality of life.
All associations statistically significant at p<0.05.
SES: socioeconomic status, BMI: body mass index, PTSD: post-traumatic stress disorder, NCD: non-communicable disease,
ART: antiretroviral therapy, QoL: quality of life.

Factors associated with QoL
Factors associated with QoL were grouped into three categories: sociodemographic,
clinical and therapy-related factors. Only one study did not find any statistically significant
association between risk factors and QoL (44). Table 1 shows the frequency of studies reporting
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statistically significant associations between QoL and risk or protective factors, after adjustment.
A summary of these factors and their positive or negative impact on QoL is found in table 2.

Sociodemographic factors
Age was the most frequently reported factor: most studies found that older age was
associated with poorer QoL (27,28,35), especially the physical domain (19,33,41,45,49). Level
of education was also frequently reported. Specifically, QoL was higher when patients were
literate or educated (23,26,44), and when patients had reached a secondary level of education or
higher (18,33,41). Being employed or having a regular or high source of income were associated
with higher QoL (28,34,37), specifically the physical, mental, psychological, and social domains
(19,23,24,27,41). Women experienced poorer QoL in the physical, mental, and social
relationships domains (19,32,39,56). Regarding marital status, higher scores were measured in
married patients or patients cohabiting with or having a stable partner (21,33,35). Similarly,
receiving social or family support was associated with higher QoL scores (23,24,33,34,41,44,51).
Residing in a rural area was associated with poor QoL (18,23,34). There was a consensus that
food security increased QoL scores (39,41,57). Also, malnutrition (24,33) and poor diet diversity
(22) were associated with lower scores. Findings for the association between body mass index
and QoL were inconsistent based on the three studies investigating this factor. Patients with
abdominal obesity (21) or underweight (23) had poorer physical scores whereas being
overweight increased mental scores (41). Knowledge of the partner's HIV status or disclosure of
one’s own status were associated with better QoL (18,21,32). Stigma negatively affected
psychological and mental domains of QoL (33,34,57), and so did a high-risk sexual behavior
(35,53) or having more than one sexual partner (27).
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Clinical factors
A higher CD4 count (54), more specifically, a count above 200 cells/mm 3 (32,42,46,50),
or 350 cells/mm3 (21) was associated with higher QoL scores. Mental health factors such as
depressive disorders (29,40,52,54,57) psychological distress (28), mental disorder (37) or posttraumatic stress disorder (53) were associated with lower QoL scores. Patients with less severe
WHO clinical staging scored higher in most QoL domains (25,32,42), but mainly in the physical
domain (33,54). Poorer physical scores were measured in symptomatic patients (19,57).
Tuberculosis (TB) co-infection was found to have a negative association with physical (23,32)
and psychological (33) scores. Several studies reported the association of higher viral load with
lower QoL (48,54). An increase in physical and mental health summary scores at follow-up was
measured in patients who had lower baseline QoL scores (45,49).
Therapy-related factors
The effect of treatment duration or follow up time on quality of life was extensively
studied. All eleven studies measuring this association reported that longer treatment duration or
follow up time was associated with higher QoL scores. Moreover, being on ART was associated
with higher QoL scores (18,35,47), while treatment-related side effects or toxicity was
negatively associated with both physical and mental domains of QoL (34,41,48,49).
Unsurprisingly, four studies found that adherence to treatment was associated with improved
QoL (27,34,36,46).
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Factors associated with QoL in studies of “good” quality
We stratified our results according to our assessment of the quality of individual studies
(Supplementary Table 2). When evaluating factors associated with QoL in studies rated as
“good”, we found that being on ART and being employed were most frequently reported. Age,
gender and depression were also found to be main factors associated with overall or domains of
QoL. A comparison of our findings in prospective cohorts with those in cross-sectional studies
did not indicate any marked trends. However, more factors, especially sociodemographic, were
investigated in cross-sectional studies. Reasons for this trend were unclear but it is possible that
longitudinal studies focused on detecting changes or developments in specific variables of
interest, which would make analyses of other factors less meaningful.

Table 5. Risk and protective factors associated with higher or lower quality of life.
Factors associated with higher QoL
Higher education
Being employed/higher SES
Being married/cohabiting
Receiving social or family support
Being treated in an NGO
Knowing partner's HIV status/disclosing own status
Higher CD4 count
Lower WHO clinical stage
Higher baseline QoL scores
Longer treatment duration or follow up time
Receiving ART
Adhering to ART

Factors associated with lower QoL
Older age
Being a woman
Residing in a rural area
Food insecurity/malnutrition/poor diet diversity
Stigma
High-risk sexual behavior/high number of partners
Depression/psychological distress/mental
disorder/PTSD
Tuberculosis
Higher viral load
Treatment-related side effects or toxicity

QoL: quality of life, NGO: non-governmental organization, ART: antiretroviral therapy, PTSD: post-traumatic stress disorder
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Discussion
We conducted a systematic review to identify and compile the factors associated with
QoL among ART-treated HIV patients in sub-Saharan Africa to address the lack of
comprehensive overview on this issue. Our review uncovered multiple factors associated with
QoL and we categorized them into three groups: sociodemographic factors, which included age,
education, socioeconomic status, gender, marital status and social or family support; clinical
factors, which included CD4 count and mental disorder; and treatment-related factors, which
included treatment duration and ART treatment. Our findings were based on data from 41 studies
carried out in 14 countries, including countries where the number of PLHIV is the highest in the
region (i.e. South Africa, Nigeria, Kenya, and Tanzania). The populations included in our review
came from various backgrounds and settings. We were able to gather evidence from primarily
high-quality studies, and overall, the results presented in our review are reflective of the current
literature on the topic.
Sociodemographic risk factors were found to influence QoL more frequently than clinical
or treatment-related factors. This was unsurprising considering that it is simple and inexpensive
to collect patients’ characteristics and it does not require any special equipment or laboratory
analyses. As a result, more sociodemographic risk factors were included in our analyses and this
may explain why 12 sociodemographic factors were associated with QoL in three or more
studies in our review, compared with nine studies for clinical factors and only four for treatmentrelated factors. Our findings are consistent with results from prior research, notably Degroote’s
(2014) review of the determinants of QoL among PLHIV in high-income countries (59). This
review of the literature included 49 studies mainly conducted in the North America and
European countries. The author reported that social and demographic determinants of QoL such
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as gender, age, family situation, or employment similarly outnumbered clinical, psychological or
behavioral determinants of QoL, even though the authors used more subcategories to summarize
the determinants of QoL.
We found both similarities and differences between Degroote’s findings in high-incomes
countries and our own results in sub-Saharan Africa. Similarities were that several factors such
as ART, depression, stigma or social support have been extensively studied in the literature and
they were expected to influence QoL in low- and high-income settings alike. In fact, these
factors directly or indirectly influence health outcomes, regardless of the population affected, as
reported in Degroote (2014) and confirmed in our review.
The main difference between Degroote’s review and ours was that certain determinants
of QoL were only relevant in high-income countries, while others only had a significant impact
in sub-Saharan Africa. For example, anxiety disorders were associated with lower physical and
mental health in high-income countries, but this association was not investigated in any of the 43
studies in our review since screening for anxiety and certain mental health disorders are less
common in low-income countries, and those disorders only account for a small fraction of the
total burden of illness. Another example is healthy nutrition, which was a determinant of QoL in
high-income countries, but not investigated in the studies in our review. In contrast, TB is a
common comorbidity among PLHIV in sub-Saharan Africa and it was found to be negatively
associated with QoL in three studies in our review. TB was not evaluated in any of the studies
included in Degroote’s review, as it is not a health priority in high-income countries, even in
PLHIV.
Our results also complement findings from a previous systematic review assessing
changes in QoL after treatment with antiretroviral drugs in cohort studies worldwide (60). In the
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two studies conducted in sub-Saharan Africa in that review (South Africa and Uganda), ART
increased PHS and MHS domains of QoL over 1 year, with the greatest increase occurring at 12
and 16 weeks, respectively. Of the 15 studies included in our review that found an association
between ART or duration of ART and QoL, seven were prospective cohorts. In all cohort studies
but one, treatment duration or follow up time (which is a proxy for treatment duration) were at
least six months, and a statistically significant association was found between treatment/follow
up duration and overall (22), physical (32,39,57) and mental (31) domains of QoL. This confirms
that ART is one of the most significant factors affecting QoL over time and its immediate start
after diagnosis remains one of the most reliable ways to improve patients’ QoL.
Our systematic review had several strengths. First, our focus on the sub-Saharan
experience provides essential data that have not been summarized before in this region despite
the severity of the epidemic and the high prevalence and incidence rates. As shown in our
review, numerous studies assessing the QoL of ART-treated HIV patients were conducted in
sub-Saharan Africa in the last five years and a summary of their findings was overdue to inform
stakeholders and provide relevant evidence to guide decision making. Second, we identified and
reported risk factors associated with QoL that were not previously described. Specifically,
characteristics pertinent to low-income countries such as food insecurity or TB emerged as
factors influencing QoL.
Our review also had limitations. First, multiple instruments were used to measure QoL,
and although all were standardized and previously validated, their diversity implies a certain
heterogeneity when combining results across studies. Some measures provided by instruments
such as MOS-HIV are summarized into physical and mental domains of QoL, while other
instruments assess as many as nine different domains (e.g. Functional Assessment of HIV
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Infection [FAHI] or SF-36). However, the impact of this heterogeneity is limited since this
review did not specifically seek to assess how individual domains of QoL were influenced by
various factors. Second, we included studies published from 2007 to 2019 and during this long
timespan, access to ART considerably increased in sub-Saharan Africa. It is likely that the
factors reported by PLHIV in the late 2000s vary from those reported in the late 2010s because
of the difference in the availability of treatment during those two periods (61). Finally, sample
sizes varied across studies and it is likely that chances of detecting statistically significant
associations between certain factors and QoL were increased with larger sample sizes. Further
exploration is warranted to assess how this issue affect our findings.
Conclusion
The QoL of ART-treated PLHIV in sub-Saharan Africa is mainly driven by
sociodemographic, clinical and treatment-related risk factors similar to those affecting the QoL
of PLHIV in the rest of the world. Yet, risk factors still rampant in poor- and middle-income
countries such as TB and food insecurity have a non-negligible impact and should be monitored
closely.
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Appendix
Supplementary Table 1. Search terms for Medline (May 7, 2019).
1
2
3
4
5
6
7

8

9

10
11

Search Term

Number
of Hits

HIV-1/ or HIV-2/ or HIV/ or HIV Seropositivity/
hiv infections/ or acquired immunodeficiency syndrome/
(hiv or aids).ti,ab,kw.
1 or 2 or 3
"Quality of Life"/
("Quality of Life" or QOL or HRQoL or "Health-related quality of
life").ti,ab,kw.
5 or 6
africa/ or "africa south of the sahara"/ or africa, central/ or cameroon/
or central african republic/ or chad/ or congo/ or "democratic republic
of the congo"/ or equatorial guinea/ or gabon/ or africa, eastern/ or
burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or
somalia/ or south sudan/ or sudan/ or tanzania/ or uganda/ or africa,
southern/ or angola/ or botswana/ or lesotho/ or malawi/ or
mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/
or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or
liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra
leone/ or togo/
(Angola or benin or botswana or burkina faso or burundi or cameroon
or cape verde or "central african republic" or chad or congo or "cote
d'ivoire" or djibouti or eritrea or ethiopia or gabon or gambia or ghana
or guinea or kenya or lesotho or liberia or malawi or mali or
mauritania or mozambique or namibia or niger or nigeria or rwanda or
senegal or "sierra leone" or somalia or saharan or sudan or swaziland
or tanzania or togo or uganda or zambia or Zimbabwe).ti,ab,kw.
8 or 9
4 and 7 and 10

665
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Supplementary Table 2. Characteristics and key findings of 41 articles included in the narrative review.
Author, Year
Country

Sackey,
2018
Ghana
MutabaziMwesigire,
2015
Uganda
Deribew,
2013
Ethiopia

Weiser,
2012
Uganda

Study Design,
Follow-up time or
dates, Sample Size

6 mos. follow up
N=152

6 mos. follow up
N=586

6 mos. follow up
N=455

median 2.1 yrs.
follow up
N=406

Age
Gender

𝑥 40 yrs.
84.1% women

≥18 yrs.
66% women

𝑥 33.4 yrs.
59.4% women

median 35
yrs.
72% women

First Line
Regimen,
Treatment
duration
ART
>6 mos.

Population Description

Setting

Risk of Bias Rating: “Good” – Prospective Cohort
Multicenter (six
45.7% married. 82.2%
district hospitals
employed.
in Accra)

QoL
Instrument

Factors associated with overall or domains of QoL

EQ-5D*

Food security, high diet diversity, longer follow up
time (higher)

60% married. 82%
employed. 74% CD4 count
101–350 cells/μL.

Mulago National
Referral Hospital.

MOSHIV#,
GPGI$

PHS: Lower education level, probable depression
and higher WHO stage (lower).
MHS: Female gender (lower). Study visit (6 mos.)
(higher)
GPGI: Alcohol consumption, lower education level,
probable depression (lower)

88.6% employed. 𝑥 CD4
cell count 383.7 cells/μl.

Jimma, Nekemte
and Adama
hospitals

WHOQOLHIV
BREF**
(Amharic
version)

Common mental disorder (moderate to very high)
(lower physical and mental QoL). No source of
income (lower mental QoL)

ART
median 13.9
mos.

43.6% married. 30.3%
unemployed. Median CD4
cell count 197.5 cells/μl.

Uganda AIDS
Rural Treatment
Outcomes
(UARTO).
Regional Referral
Hospital Immune
Suppression
Syndrome (ISS)
Clinic

MOS-HIV

PHS: Severe food insecurity, increasing age, female
gender, being married (lower). Increased duration
of ART (higher)

Public-sector
ART programme
in the Free State
Province

EQ-5D

Home-based
AIDS Care
Project.

MOS-HIV

ART
Not Reported

ART
Not Reported

Wouters,
2009
South Africa

24 mos. follow up
N=268

𝑥 37.9 yrs.
65.3% women

ART
Treatment
naive

100% CD4 < 200 cells/μL
and/or WHO stage IV.
47.8% some secondary
education.

Stangl, 2007
Uganda

12 mos. follow up
N=947

𝑥 38.7 yrs.
75% women

HAART
Treatment
naive

35.2% married or
cohabiting. 53.5% primary
education. 𝑥 CD4 cell count
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After 12 mos. of ART: physical and emotional QoL:
CD4 count, viral load, treatment outcome (higher).
Adverse effects (lower). Physical QoL: emotional
QoL (higher).
After 24 mos. of ART: physical and emotional QoL:
CD4 count, viral load, treatment outcome (higher).
Physical QoL: emotional QoL (higher)
PHS: increased time on HAART, higher CD4 cell
count, and religion (Protestant) (higher).
Source of income (being dependent), higher

124.1 cells/μl

Yaya, 2019
Togo

May-Aug 2016
N=880

depression scores, WHO stage III-IV (lower).
MHS: increased time on HAART, higher CD4 cell
count, and religion (Protestant) (higher). Source of
income (being dependent), higher depression scores
and increased plasma HIV-1 copies (lower).

Risk of Bias Rating: “Good” – Cross-sectional
51.7% living in couple.
Multicenter.
17.6% no formal education.
Centrale and Kara
71.7% CD4 count >350
regions
3
cells/mm .

𝑥 39.6 yrs.
78.4% women

90.5% on
ART
Not Reported

52.6% married. 46.7%
secondary education level.

Etenyi, 2018
Kenya

Dec 2015-May
2016
N=501

range 36-45
yrs.
69.5% women

Tenofovirbased or
Zidovudinebased
>6 mos.

Nyongesa,
2018
Kenya

Nov 2016-Mar
2017
N=84

𝑥 40.1 yrs.
78.6% women

ART
Not Reported

Biraguma,
2018
Rwanda

Nov 2014-June
2015
N=794

𝑥 38 yrs.
64.6% women

87.9% on
ART
Not Reported

Gebremicha
el, 2018
Ethiopia

Apr-May 2016
N=505

𝑥 36.2 yrs.
50.3% women

ART
Median 46
mos.

Surur, 2017
Ethiopia

Apr-May 2014
N=400

60.8% ≥ 30
yrs.

HAART
Not Reported

WHOQOLHIV BREF

Education level (secondary and higher), health
region (Kara), ART, knowledge of partner’s HIV
status (good global QoL).

Kenyatta
National Hospital
Comprehensive
Care Center

MOS-HIV

PHS: regular source of income, zidovudine-based
regimen (higher). Having symptoms, female gender,
age above 40 y, inability to cope with HIV,
lopinavir/ritonavir-based regimen (lower)
MHS: Inability to cope with HIV, presence of any
symptom, presence of pain, types of ART regimen
(lower).

56% married. No more than
primary level of education.

Comprehensive
Care and
Research Clinic

RAND SF36##

Elevated depressive scores (lower).

63.9% married. 59.9%
primary education level.
67.4% lived in urban area.

Multicenter
(Kigali City,
Southern and
Eastern
provinces)

MOS-HIV

74.1% males / 62.2%
females married. 92.0%
males / 77.2% females
employed.

Public health
facilities in West
shoa Zone

WHOQOLHIV BREF

42.8% married. 35.5%
secondary education. 44.5%

Gondar
University

WHOQOLHIV BREF
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PHS: currently married (higher). CD4 counts <350
cells/μL, abdominal obesity, physically inactive or
hypertensive (lower).
MHS: currently married (higher). Did not disclose
HIV+ serostatus, abdominal obesity, tobacco users
(lower).
In both genders: education (illiterate) (I, SR, E),
occupation (unemployed) (P,PSY, SR, E),
undernutrition (BMI < 18.5 kg/m2) (male: P, I, E;
female: P, PSY, I, E), depression (all domains),
tuberculosis (male: all domains except E and SRPB;
female: all domains except SRPB), anemia (male: P,
PSY, E; female: P, PSY, I, E) and no family support
(male: PSY, SR, SRPB; female: P, PSY, SR, SRPB)
(lower).
In females: rural residence (male: PSY, SR, SRPB;
female: P, PSY, SR, SRPB) (lower).
Gender (PSY, SRPB), age (PSY), residence (I),
educational status (SR, E), marital status (E), and

CD4 count ≥500 cells/mm3.

54.7% women

Ndubuka,
2017
Botswana

Apr 2012-Not
Reported
N=456

𝑥 43.9 yrs.
68% women

Mwesiga,
2015
Uganda

Sept-Dec 2013
N=345

median 35
yrs.
71.2% women

Mekuria,
2015
Ethiopia

Tesfay, 2015
Ethiopia

Sept 2012-Apr
2013
N=664

𝑥 37.6 yrs.
63.6% women

Feb-Apr 2012
N=494

women: 𝑥
35.5 yrs.
men: 𝑥 39.8
yrs.
50.6% women

HAART
>5 yrs.

83.8% on
HAART
Not Reported

Referral Hospital

(Amharic
version)

WHO stage (all domains).

17.5% married. 45%
employed. 77.7% CD4
count ≥350 cells/mm3.
98.2% full viral
suppression.

Six ART clinics
in southeastern
Botswana

WHOQOLHIV BREF

Older age (I, SR, E, SRPB), being married (P, SR),
being unemployed (P, PSY, E, SRPB), poor health
status (all domains), coping with life by contacting a
person with ART (S), no self-education on HIV (all
domains), missing ≥1 appointment (P, I, SR),
missing ART ≥1 time in the last 2 days (PSY, E),
not understanding circumcision prevents HIV (all
domains except PSY), not being aware of the
multiple concurrent partnership program (P, PSY,
I), having sex with ≥1 partner (P, PSY, SRPB), not
discussing condom with the sex partner or not
having a partner (SR) (lower).
No coping experience (I, SRPB) (higher).

44.6% married. 40.6%
secondary education level.
CD4 count 𝑥 537
cells/mm3.

Mildmay Uganda
care center

WHOQOLBREF

Depression with pain comorbidity (P, PSY, E)
(lower).

Nevirapinebased or
Efavirenzbased
Mean 26 mos.

52.1% married or
cohabiting. 50.3% work full
time. 𝑥 CD4 count 150
cells/μL.

Ten healthcare
facilities

WHOQOLHIV BREF
(Amharic
version)

HAART
Mean 44 mos.

32% women, 59% men
married. 71.2% women,
95.1% men employed.
Median CD4 cell counts:
women: 366 cells/mm3,

Five health
institutions in
Mekelle

WHOQOLHIV BREF
(Tigrigna
version)
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Male gender (SR), secondary/or tertiary education
(E), being married or cohabiting (SR), a
government health center facility (SR), social
support (SR, SRPB), obtaining sufficient food with
nutritional value (all domains except SRPB), having
the opportunity to find or maintain a job (all
domains except SR), the possibility to share
common resources with other people (PSY, E)
(higher).
Increased age (P, SR, I), TB (PSY), being bed
ridden (P, SRPB, I), WHO clinical stage IV (P, SR),
depressive symptoms (all domains), stigma (all
domains except P), worrying about the
consequences of HIV disclosure (SRPB), worrying
about taking care of family when passed away (P,
SRPB, I) (lower).
No psychosocial support outside family (women: P,
SR; men: P), WHO stage I-III (women: SRPB),
illiteracy (women and men: P, SR), rural residence
(women: PSY, I, E), no psychosocial support from
family/friends (women: PSY, SR), high perceived

men: 296 cells/mm3.

stigma (women: PSY; men: all domains except SR
and E), younger age (women: SR), family size <=2
(women: SRPB; men: E), recent side effect (women:
I), non-adherence (men: E, SRPB), being
unmarried (men: SR) (lower).
≥ average monthly income (women: P, SR, E; men:
I, SR), <36 mos. on ART (women: P, SR), <36 mos.
since diagnosis (women: E), lower WHO stage
(men: all domains except SR and SRPB) (higher)
Aggregated PCS and MCS: age, gender, religion,
occupation, clinical symptoms, chronic illnesses,
adherence, and duration on ART.

Mûnene,
2014
Kenya

Feb-Apr 2013
N=392

𝑥 41.4 yrs.
68.9% women

HAART
Median 4.5
yrs.

42.3% married. 50.3% paid
employment.

Nyeri Provincial
General Hospital

+SF-36

Olisah, 2011
Nigeria

Sept-Dec 2006
N=310

𝑥 35.5 yrs.
68.4% women

ART
Mean 17.7
mos.

52.9% married. 38.7%
unemployed. 14.2%
depressive disorder.

Ahmadu Bello
University
Teaching
Hospital

WHOQOLBREF

Depressive disorder (all domains except E) (lower).

MOS-SF12

PCS: Increasing age, financial difficulties paying for
HIV biological monitoring in the previous 3 mos.,
living below the poverty line, BMI <= 18.5 kg/m2,
CD4 count <100 cells/μl, hospitalization during the
previous 6 mos., experience of AIDS-defining
events, side-effects during the previous 4 weeks
(lower). Female gender, university educational level
(higher).
MCS: Semi-urban area of residence, financial
difficulties paying for HIV biological monitoring in
the previous 3 mos., living below the poverty line,
side-effects during the previous 4 weeks (lower).
Increasing age, being a homeowner, always having
at least two meals per day, BMI >25 kg/m2 and
strong moral support (higher).

Boyer, 2012
Cameroon

Sept 2006-Mar
2007
N=1985

𝑥 38.5 yrs.
70.7% women

ART
>6 mos.

Fan, 2011
Malawi

Sept 2005
N=267

𝑥 37.8 yrs.
72.7% women

HAART
Not Reported

Abera, 2010
Ethiopia

Aug-Oct 2007
N=422

𝑥 32.3 yrs.
56.4% women

HAART
>3 mos.

Patel, 2009
Zimbabwe

June-Aug 2007
N=96

𝑥 38.5 yrs.
100% women

ART
Mean 14.8

22.6% married. 𝑥 CD4
count at ART initiation
137.7 cells/ml.

EVAL– French
National Agency
for Research on
AIDS and
Hepatitis
(ANRS).
27 hospitals

48.3% married. 87.4%
employed. 48% CD4 count
<200 cells/mm3 (AIDS).

Rainbow HIV
Clinic

38.4% married. 41%
employed.
35.4% married. 39.6%
unemployed. 𝑥 CD4 count
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Yirgalem,
Hawassa and
Shashemene
hospitals
Chitungwiza
Regional Hospital

%MOS-SF-

36

WHO stage III-IV (V, MH) (lower). AIDS (CD4
count <200 cells/mm3) (PF, BP, PCS) (lower).

SF-36
(Amharic
version)

Duration of treatment >12 mos. (RP, RE), CD4 cell
count >200 cells/mm3 (BP, VT, RE), adherence to
doses of HAART (PHS), and adherence to schedules
of HAART (all domains except VT) (higher).

MOS-HIV

ART (overall score, MHS) (higher).

mos.
Magafu,
2009
Tanzania
Bajunirwe,
2009
Uganda

148.9 cells/mm3.

May 2007
N=329

mean 40.9
yrs.
66% women

HAART
>6 mos.

33.1% married. 7.3%
unemployed.

Kagera regional
hospital

Apr-Dec 2006
N=330

≥18 yrs.
67.2% women

ART
>6 mos.

43.6% married. 20.3% CD4
cell count <200 cells/mm3.

Kitagata and
Mbarara hospitals

Jong, 2016
Tanzania

Aug-Sept 2015
N=163

𝑥 41 yrs.
76% women

91.4% on
ART
Not Reported

69.9% did not work for
pay. 𝑥 CD4 count 276.9
cells/mm3.

Six HIV clinics

MOS-SF12

Gender (male), high social capital (higher).

Mweemba,
2008
Zambia

Not Reported
N=160

𝑥 36.5 yrs.
83.6% women

86.9% on
ART
Not Reported

40.6% married. 46.9%
employed. 𝑥 CD4 count
358 cells/μl.

Two rural and
two urban
antiretroviral
clinics

WHOQOLHIV

Younger age (SRPB), being asymptomatic (SRPB)
(higher).

𝑥 36.4 yrs.
61.7% women

Efavirenzbased or
Nevirapenbased or
Other
>6 mos.

WHOQOLHIV BREF
(Amharic
version)

No source of income (PSY, SR, I, E), no social
support (all domains except SRPB), severe acute
malnutrition (all domains except E) (lower).

Alemayehu,
2018
Ethiopia

6 mos. follow up
N=439

Wubshet,
2014
Ethiopia

12 mos. follow up
N=487

median 31
yrs.
57.7% women

ART
Treatment
naive

Takada,
2012
Uganda

median 2.1 yrs.
follow up
N=422

𝑥 34 yrs.
71% women

HAART
Treatment
naive

Alibhai,
2010
Uganda

12 mos. follow up
N=130

median 35
yrs.
62% women

Nevirapinebased or
Efavirenzbased

Risk of Bias Rating: “Fair” – Prospective Cohort
Abdrafi Health
center, Metema
14.1% unemployed.
Hospital, Humera
Median CD4 count 419
Hospital,
cells/μL.
University of
Gondar Hospital
University of
Gondar Teaching
44% married. 41.5%
Hospital, Gondar
employed. Median CD4
Health Center,
cell count 93 cells/μL.
Azezo Health
Center

SF-36
(Swahili
version)
MOS-HIV
(Lunyankol
e version)

WHOQOLHIV BREF
(Amharic
version)

44% married. 85% primary
education or more. CD4
count median 203
cells/mm3.

Mbarara Regional
Referral Hospital

MOS-HIV

42% married. 65%
employed. Median CD4
cell count 144 cells/mm3.

Communitybased
antiretroviral
treatment

MOS-HIV
(Rutooro
version)
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Chronic diseases comorbidity (MHS, PHS) (lower).
PHS: CD4 count ≥200 cells/mm3, informational
social support (higher).
MHS: past or recent alcohol use (lower).

Follow up time (PSY, P), male gender (P, overall),
disclosure of HIV status (PSY, SR), CD4 count
≥200 cells/mm3 (P, I, SR, E, overall), WHO stage
III-IV (all domains except P and E), good baseline
QoL (all domains) (higher).
Tuberculosis co-infection (P, overall) (lower).
PHS: Increased age, increased symptom index score,
depression, food insecurity, internalized and enacted
stigma (lower). Increased follow up time (higher).
MHS: Increased symptom index score, depression,
unemployment, food insecurity, internalized and
enacted stigma (lower). Increased follow up time
(higher).
PHS: Lower baseline PHS scores, younger age
(higher).
MHS: Lower baseline MHS scores, younger age
(higher).

~12 mos.

Oladeji,
2017
Nigeria

March-Aug 2011
N=828

𝑥 41.3 yrs.
71% women

Vo, 2016
Ethiopia

June 2012-Apr
2013
N=1180

median 34
yrs.
61% women

Asangbeh,
2015
Cameroon

Sept-Nov 2013
N=202

≥21 yrs.
NR

McInerney,
2008
South Africa

Not Reported
N=149

𝑥 35.5 yrs.
64% women

90% on
HAART
Not Reported
ART
Male: median
33 mos.
Female:
median 160
mos.

(CBART)
program.
Risk of Bias Rating: “Fair” – Cross-sectional
University
57.4% married. 58.7% at
College Hospital,
least elementary school.
Ibadan
Starting ART
Late (LSTART).
65% men, 46% women
Six secondarymarried. 72% less than
level urban
secondary education levels.
hospitals in
Oromia State

ART
Not Reported
ART
Mean 4 mos.

34.3% married. 42%
employed.

WHOQOLHIV BREF

Suicidal behavior (all domains) (lower)

^HAT-QOL

Psychological distress (mild, high), unemployment,
late ART initiation, being a man between the ages of
30–39 yrs. (vs. <=29), being a man reporting the last
sexual encounter occurring in the previous 3 mos. to
1 year (vs. in the past 30 days) (lower).

Mbengwi district
hospital

WHOQOLBREF

Depressive symptoms (lower).

Clinics in Durban

MOS-SF36
(English
and isiZulu
versions)

Physical function: Fewer comorbid medical
problems, social support, a greater length of time on
ART (higher).
Depressive disorder (all domains except SR),
gender (SR), and presence of medical problems (P,
PSY) (lower).
Highest educational level (all domains except SR),
perceived level of social support (P, SR, overall),
number of dependent (P), age (PSY, overall),
socioeconomic status (E, overall) (higher)
PTSD (PF, MF, RF, SF, HP), number of negative life
events (PF, MF), age (PF), number of symptoms
(PF), risky sexual practices (P)

Adewuya,
2008
Nigeria

Not Reported
N=87

≥18 yrs.
56.3% women

ART
Mean 29 mos.

23% married. 41.4% low
socioeconomic status.

Living Hope Care
center

WHOQOLBREF

Olley, 2008
Nigeria

Not Reported
N=56

𝑥 36.5 yrs.
53% women

HAART
Not Reported

55% married. 𝑥 12 yrs. of
education.

Nigerian Air
Force Hospital

MOS-HIV30

Parcesepe,
2018
Ethiopia

Not Reported
(Secondary
Analysis)
N=722

≥18 yrs.
100% women

ART
Treatment
naive

50.4% currently in
relationship. 60.9% ever
attended school.

LSTART. Six
HIV clinics in the
Oromia region

HAT-QoL

Education (never attended school) (overall function)
(lower)

Tomita,
2014
South Africa

maximum 9 yrs.
follow up
N=51

𝑥 25.9 yrs.
100% women

ART
Treatment
naive

75% married or stable
partnership. 54.9% at least
grades 11 or 12 of
schooling. 𝑥 CD4 count

CAPRISA 002
ART Cohort.

$$FAHI

ART (overall, PWB, EWB, SWB), being
married/having a stable partner (overall, PWB,
FGWB, CF) (higher).
Age 21–24y and 40–59y (SWB), being single

Risk of Bias Rating: “Poor” – Prospective Cohorts
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488 cells/mm3.
Bhargava,
2010
South Africa

6 mos. follow up
N=102

Pitt, 2009
South Africa

48 weeks follow
up
N=295

𝑥 38.5 yrs.
65.5% women

𝑥 34 yrs.
74% women

ART
Mean 67.4
days
Nevirapinebased or
Efavirenzbased
Treatment
naive

(overall, FGWB, CF), high-risk peno-vaginal sex
act (SWB) (lower).

𝑥 CD4 count 181.5
cells/mm3.

16 public clinics

Median CD4 count 88
cells/mm3.

Hannan Crusaid
Treatment Centre

EQ-5D

Increased yrs. of education, emotional support,
increased CD4 count (higher).

MOS-SF36

PHS: after 48 weeks, higher pre-HAART scores,
baseline viral load <=5.0 log copies/ml, older age,
drug toxicity (lower).
MHS: after 48 weeks, higher pre-HAART scores
(lower).

Risk of Bias Rating: “Poor” – Cross-sectional
mean 34.8
Ogbuji, 2010 2004-2007
ART
54.1% married. 60.7%
Three HIV care
&QOLS
yrs.
No statistically significant associations found
Nigeria
N=514
Not Reported employed.
support centers
65.5% women
QoL = quality of life; HRQOL = health-related quality of life; NGO = non-governmental organization; PTSD = post-traumatic stress disorder
**WHOQOL-HIV (Domains: Physical = P, Psychological = PSY, Level of Independence = I, Social Relationships = SR, Environment = E, Spirituality/Religion/Personal
Beliefs = SRPB). #MOS-HIV = Medical Outcomes Study-HIV. %MOS-SF-36 = Medical Outcomes Survey Short Form 36 (Physical functioning = PF, Role limitation due
to physical problems = RP, Role limitation due to emotional problems = RE, Vitality = V, Mental health = MH, Social functioning = SF, Bodily pain = BP, General health =
GH, Physical component summary = PCS, Mental component summary = MCS). ##RAND SF-36 = RAND 36-Item Short Form Survey. *EQ-5D = EuroQol Five
Dimensions Questionnaire. EQ-5D-3L = EuroQoL Five Dimensions Three-level. ^HAT-QOL = HIV/AIDS-Targeted Quality of Life (Overall function = OF, life
satisfaction = LS, health worries = HW, financial worries = FW, medication worries = MW, HIV mastery = HIVM, disclosure worries = DW, provider trust = PT, sexual
function = SF). $GPGI = Global Person Generated Index. $$FAHI = Functional Assessment of HIV Infection (Physical well-being = PWB, emotional well-being = EWB,
functional/global well-being = FGWB, social well-being = SWB, cognitive functioning = CF). +SF-36 = 36-Item Short-Form Health Survey (Bodily pain = BP, general
health = GH, mental health = MH, physical function = PF, limitation in role due to emotions = RE, limitation in role due to physical health = RP, social function = SF,
vitality = VT, physical health summary = PHS, mental health summary = MHS). &QOLS = Quality of Life Scale
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Abstract
Introduction: Few studies have investigated the factors associated with the physical and
mental domains of quality of life (QoL) among HIV patients in western and central Africa,
and none in Lomé, Togo. The objective of this study was to assess the QoL of adult HIV
patients of a community health clinic with a strong social support component in Lomé and
identify factors associated with QoL in this population.
Methods: A cross-sectional study was conducted at Espoir Vie Togo in July and August
2019 with 147 consecutive adult HIV patients receiving long-term antiretroviral therapy.
QoL was assessed using the medical outcome study-HIV health survey (MOS-HIV). We
identified risk and protective factors associated with physical health summary (PHS) and
mental health summary (MHS) scores using multiple linear regression analyses with stepwise
model selection.
Results: Mean (SD) PHS and MHS scores were 80.7 (13.9) and 66.7 (11.1), respectively.
Younger age, male gender, food security, the absence of treatment-related side effects, and
self-evaluated “excellent or very good” health status were significantly associated with
higher PHS scores. Male gender, a higher education level, food security, family or social
support and self-evaluated “excellent or very good” and “good” health status were
significantly associated with higher MHS scores.
Conclusions: Patients treated at the clinic had an overall high QoL, which was associated
with socio-demographics risk factors also found in other studies in western and central
Africa. Our findings suggest that community health clinics with a strong social component
positively impact the QoL of people living with HIV in western and central Africa.
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Introduction
The life expectancy of HIV patients who initiate antiretroviral therapy (ART) early
and adhere to treatment has increased substantially in the last decade [1,2]. AIDS-related
mortality decreased by 42% from 2004 to 2017 in eastern and southern Africa, and by 24%
in western and central Africa [3]. As a result, HIV prevalence in the WHO Africa region is
now steadily increasing [4]. In 2018, an estimated 110,000 people were living with HIV in
Togo, of which 72,745 (66.1%) were registered in healthcare facilities, and 64,842 (59%)
were receiving life-saving ART [5]. Because of the shift of HIV from a fatal disease to a
chronic condition, quality of life (QoL) has emerged as a significant medical outcome in HIV
management. Retaining HIV patients in long-term care so they achieve viral suppression is
one of the key steps of UNAIDS’ 90-90-90 treatment target, yet it remains a major challenge
in sub-Saharan Africa [6]. One important way to overcome this challenge is to ensure
patients maintain a high QoL as they cope with their disease. Optimizing treatment and care
based on the risk factors affecting QoL may lead to an improvement in the overall
management of people living with HIV (PLHIV) and ensure they effectively stay in care,
remain asymptomatic and no longer transmit the disease.
Few studies investigating the determinants of QoL were conducted in western and
central Africa. In Ghana, a prospective cohort of 152 PLHIV showed that food security and
high diet diversity were associated with improvements in QoL scores over time [7]. In
Nigeria, a cross-sectional study found that depressive disorder, lower socioeconomic status
and education level and poor social support were associated with lower QoL scores [8].
Another cross-sectional study in Nigeria reported the association of suicidal behavior with
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lower QoL scores [9]. More recently, a study conducted in inland regions of Togo suggested
that patients on ART or those with at least a secondary education, or who had disclosed their
HIV status or lived in the rural region of Kara in northern Togo, had a significantly higher
overall QoL [10]. However, no research has been conducted in Lomé, the Togolese capital
and a dynamic, growing urban area. Moreover, no research has been conducted in a
community healthcare setting, where patients receive social support such as financial
assistance or sponsored meals in addition to long-term care, and are more likely to adhere to
treatment because of the clinic’s patient-centered approach [11]. The current study was
undertaken to assess the QoL of adult ART-treated HIV patients in such a clinic in Lomé,
Togo, and identify the risk and protective factors associated with QoL.
Methods
Study Setting and Population
We conducted a cross-sectional survey at Espoir Vie Togo (EVT) in July and August
2019. EVT is a community health clinic and a non-governmental organization whose mission
is to provide treatment and social support to PLHIV in Togo [12]. It currently manages
approximately 3,500 patients and has clinics in Lomé, the capital, and in Aného and Sokodé.
Study participants were consecutive men and women PLHIV 18 years or older who visited
the clinic in July and August 2019. Eligibility criteria were: >=18 years, a confirmed HIV
diagnosis and currently taking ART. Pregnant women were excluded. Patients were treated
with an ART regimen consisting of two nucleoside reverse transcriptase inhibitors (NRTIs)
(usually lamivudine [3TC] and tenofovir disoproxil fumarate [TDF]), and one non67

nucleoside reverse transcriptase inhibitor (NNRTI) (usually efavirenz [EFV]) or one protease
inhibitor (usually atazanavir or atazanavir/ritonavir).
Sample size
We estimated the sample size based on a fixed model and R-squared increase for
linear multiple regression. We assumed a medium population effect size, a power of 80%, a
significance level of 5%, and 15 predictors. Using G*Power software Version 3.1.9.4, a
sample size of 140 was generated [13].
Data Collection
The principal investigator (HS), a clinical psychologist (JMAE), and a youth outreach
coordinator (EH) interviewed the participants in French using the medical outcome studyHIV health survey (MOS-HIV) before or after the doctor visit. Each survey lasted 10 to 15
minutes. Approximately ten participants were interviewed daily, one at a time, in a private
consultation room. Participants were given a 500 CFA (~ US $0.85) token as reimbursement
for travel expenses. Prior to administering the survey, the following characteristics were
collected from the medical records: gender, age, CD4 count, viral load, health status,
serostatus (symptomatic or asymptomatic), treatment duration, ART regimen, line of
treatment, treatment adherence and treatment-related side effects. Participants reported data
on their education, employment, marital status, HIV status disclosure, social or family
support, and alcohol use. Food insecurity was measured with Kleinman’s validated one-item
screening question [14]. Body mass index (BMI) was calculated from height and weight
measurements taken prior to the interview. Adherence was defined as not missing two
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consecutive doctor’s appointments and taking all pills in the week preceding an appointment.
All data were collected on a password-protected tablet computer.
Quality of Life Measure
The MOS-HIV was used to assess QoL in our study population [15]. The French version of
the survey was obtained from Mapi Research Trust (Lyon, France). The MOS-HIV is a
disease-specific instrument that has been previously validated in various settings in subSaharan Africa [16,17]. It includes 35 items investigating health transition (HT) and 10
dimensions of QoL: general health perceptions (GH), pain (P), physical functioning (PF),
role functioning (RF), social functioning (SF), energy/fatigue (EF), mental health (MH),
health distress (HD), cognitive functioning (CF), quality of life (QL). Raw scores are
computed then transformed to a 0 to 100 scale, with higher scores indicating better QoL.
Ethical Approval
Ethical approval to conduct this study was obtained from the Comité de Bioéthique pour la
Recherche en Santé (031/2019/CBRS) in Togo and from the Committee for the Protection of
Human Subjects of the University of Texas Health Science Center at Houston (HSC-SPH-190357) in the United States. EVT granted their permission and provided logistics support for
this study. All participants provided oral informed consent prior to study inclusion.

Statistical Analysis
Descriptive statistics were presented as proportions for categorical variables, and means and
standard deviations (SD) for continuous variables. For each participant, a physical health
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summary score (PHS) and a mental health summary score (MHS) were generated from the
dimensions of QoL. A factor analysis with oblique rotation was performed to obtain factor
score coefficients, which were used to compute the PHS and MHS scores [18]. The scores
were standardized to a scale with a mean of 50 and standard deviation of 10. These
standardized PHS and MHS scores were used as the dependent variables in two separate
regression analyses. Cronbach’s alpha coefficients were calculated for dimensions with more
than one item to measure the internal consistency of the questionnaire. An alpha greater than
0.70 was selected to demonstrate adequate reliability and was considered satisfactory for
comparisons.
Two multiple linear regression analyses were fitted to determine the factors associated with
QoL, one with PHS as the dependent variable, and the other with MHS as the dependent
variable. All other measured variables were evaluated as candidate independent variables.
Correlations among them were examined for multicollinearity. For each summary score
(PHS and MHS), stepwise model selection was performed to determine the subset of
variables best defining the relationship between the independent variables and the specific
summary score under investigation. The variables included at the start of model selection
were the ones found to have a p-value greater than 0.1 upon univariate analysis. The most
parsimonious model for each summary score was selected and validated using a training and
validation set. P <0.05 was set as the level of statistical significance. SAS software, Version
9.4 was used for all data analyses [19].
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Table 6. Baseline characteristics of 147 HIV patients at Espoir Vie Togo.
Characteristic
Gender
Female
Male
Age (years)
Education
None
Primary
Secondary
University
Employment
Unemployed or retired
Employed part time
Employed full time
Marital status
Single
Married/cohabiting
Divorced/separated/widowed
BMI (kg/m2)
HIV status disclosure
Social/family support
Alcohol use
Never
<1/month
2-4/month
>2-3/week
Food insecurity
HIV serostatus (n=146)
Symptomatic
Asymptomatic
CD4 count (cells/µl)
Viral load (n=89)
Undetectable
≤40 copies/ml
>40 copies/ml
Treatment duration (months) (n=144)
Art regimen (n=140)
3TC + TDF + EFV
3TC + TDF + ATV or ATVr
Other
Line of treatment
1st
1st substituted
2nd
Adherence
Side effects
Self-evaluated health status
Excellent/very good
Good
Poor/mediocre

N (%) or Mean (SD)
108 (73.5)
39 (26.5)
43.2 (11.6)
25 (17)
48 (32.7)
69 (46.9)
5 (3.4)
32 (21.8)
38 (25.8)
77 (52.4)
26 (17.7)
59 (40.1)
62 (42.2)
23.8 (5.5)
126 (87.5)
111 (75.5)
88 (59.9)
39 (26.5)
13 (8.8)
7 (4.8)
91 (61.9)
15 (10.3)
131 (89.7)
513.5 (350.2)
60 (67.4)
6 (6.7)
23 (25.9)
94.3 (60.3)
88 (62.9)
37 (26.4)
15 (10.7)
34 (24.8)
55 (40.2)
48 (35)
135 (93.8)
33 (22.5)
52 (35.4)
83 (56.5)
12 (8.2)

3TC=lamivudine, TDF=tenofovir, EFV=efavirenz, ATV=atazanavir, ATVr=atazanavir/ritonavir
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Results
Of the 157 patients who were approached for study participation, 147 agreed to
participate, yielding a participation rate of 94%. 108 (73.5%) participants were female (Table
1). The mean age (SD) was 43.2 (11.6) years and the mean (SD) duration of treatment was
94.3 (60.3) months. Most patients had disclosed their HIV status to their partner or family
(n=126; 87.5%), had family or social support (111; 75.5%), and suffered from food
insecurity (91; 61.9%).
Table 7. MOS-HIV dimensions of quality of life for 147 HIV patients at Espoir Vie Togo.
Dimension
General health
Pain
Physical functioning
Role functioning
Social functioning
Energy/fatigue
Mental health
Health distress
Cognitive functioning
Quality of life
Health transition
PHS
MHS

Mean (SD) [range]
58 (22.6) [10-95]
70.3 (23.3) [0-88.9]
90.8 (15.1) [25-100]
88.1 (28.3) [0-100]
93.2 (16.6) [20-100]
61 (14.5) [10-95]
69 (13.9) [20-100]
83.2 (16.9) [30-100]
80 (15.3) [30-100]
49 (21.9) [0-100]
57.7 (22.6) [0-100]
80.7 (13.9) [28.3-96.8]
66.7 (11.1) [30.7-87]

Cronbach Alpha*
0.78
0.77
0.77
0.78
0.77
0.76
0.78
0.79
-

*

Cronbach’s alpha coefficients were calculated for dimensions with more than one item.
Raw scores were transformed to a 0 to 100 scale.
PHS: physical health summary score; MHS: mental health summary score.

Quality of Life Scores
The mean (SD) PHS and MHS scores were 80.7 (13.9) and 66.7 (11.1), respectively.
The scores were relatively high on a 0-100 scale, and indicated an overall good QoL in the
patient population. Table 2 shows the mean, SD and range for all the dimensions of the
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MOS-HIV survey. The internal consistency of the survey was high. The Cronbach’s alphas
of the multi-item scales were adequate: GH (0.78), P (0.77), PF (0.77), RF (0.78), EF (0.77),
MH (0.76), HD (0.78), CF (0.79).
Factors Associated with Quality of Life
For PHS, age, gender, food insecurity, ART adherence, side effects and self-evaluated
health status were retained in the final model (Table 3). This subset of predictors explained
21% of the variance in PHS (R-squared = 0.21). More specifically, lower PHS scores were
associated with increasing age (p=0.01) and female gender (p=0.02), whereas higher PHS
scores were associated with food security (p=0.045), not experiencing treatment-related side
effects (p=0.03), and having an “excellent or very good” health status (p=0.003). For MHS,
gender, education, food insecurity, ART adherence, family or social support and selfevaluated health status were retained in the final model, which explained 30% of the variance
in MHS (R squared = 0.30). Lower MHS scores were associated with female gender
(p=0.02), having a primary level of education (p=0.05) and not having family or social
support (p=0.006). On the other hand, higher MHS scores were associated with food security
(p<0.0001), having an “excellent or very good” health status (p=0.001), or a “good” health
status (p=0.04).
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Table 8. Model selection of factors associated with quality of life in 147 HIV patients at
Espoir Vie Togo
Variable
Intercept
Age (years)
Gender (female)
Food security
Adherence
Side effects (absent)
Health status (ref. Poor or mediocre)
Excellent or very good
Good
Education (ref. University)
None
Primary
Secondary
Social/family support

PHS
ρ (95% CI) (x103)
R2=0.21
140.26 (60.17, 220.35)
-1.01 (-1.82, -0.21)
-25.33 (-46.40, -4.26)
19.68 (0.42, 38.94)
-25.31 (-63.23, 12.61)
26.87, 3.29, 50.44)
58.51 (20.28, 96.73)
33.19 (-2.19, 68.56)

P value
<0.001
0.014
0.019
0.045
0.189
0.026
0.003
0.066

MHS
ρ (95% CI) (x103)
R2=0.30
3.36 (2.04, 4.69)

P value
<0.001

-0.41 (-0.75, -0.074)
0.61 (0.32, 0.91)
-0.43 (-1.02, 0.16)

0.018
<0.001
0.156

0.95 (0.37, 1.53)
0.58 (0.028, 1.12)

0.001
0.040

-0.48 (-1.33, 0.36)
-0.80 (-1.59, -0.0005)
-0.41 (-1.18, 0.37)
-0.46 (-0.78, -0.14)

0.260
0.049
0.300
0.006

PHS: physical health summary score, MHS: mental health summary score, ρ: regression coefficient, ref.: reference group

Discussion
This cross-sectional study investigated the QoL of 147 ART-treated adult PLHIV in a
community health clinic in Lomé, Togo. We measured relatively high PHS and MHS scores
among patients treated at the clinic. Significant associations between physical and mental
health summary scores and age, gender, education, food security, treatment-related side
effects and self-evaluated health status were found.
Physical and mental domains of QoL measured in the EVT population were relatively
higher than those observed in previous comparable studies (i.e. studies conducted in subSaharan Africa and using the MOS-HIV survey). Etenyi (2018) investigated a Kenyan
outpatient population and reported PHS and MHS scores ranges between 60.14 (tenofovir
regimen) and 61.9 (zidovudine regimen) and 51.3 and 51.83, respectively [20]. Biraguma
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(2018) measured PHS scores of 63.96 and MHS scores of 53.43 in a Rwandan patient
population treated at public health centers [21]. It is likely that QoL scores in our population
were higher because EVT is a medical center that supports its patients socially in addition to
providing treatment in the long term. In fact, many patients receive clinic-sponsored meals
the day of their doctor visit, while others receive financial assistance for their education or to
pursue training opportunities. In addition, patients participate in a “causerie” (French for
“informal talk”) prior to seeing the doctor and collecting their prescriptions. The “causerie” is
a social worker-animated informal group talk providing patients with general disease
information and coping mechanisms to help maintain their overall well-being in good state.
All these patient-oriented elements lead to higher quality of care and better patient-provider
relationship, which ultimately contribute to better patient outcomes and higher QoL, as
suggested by a previous cross-sectional study [11].
As expected, several socio-demographic factors influenced the QoL of EVT patients.
Age and gender, two well-known determinants of health, [22,23] were associated with PHS
(age), and both PHS and MHS (gender). This confirms findings from previous research in
western and central Africa [24,25]. Among HIV patients across 27 hospitals in Cameroon,
Boyer (2012) reported lower physical component scores (PCS) but higher mental component
scores (MCS) with increasing age, after adjusting for other socio-demographic and treatmentrelated covariates. Thus, age was established as a major driver of QoL, as anticipated. The
association was positive for MCS, most likely because of the more significant role social
support plays in adolescents’ and young adults’ lives. However, the association was negative
for PCS, possibly because of physical senescence. When examining research in eastern
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Africa, similar trends were observed [26-28]. In a Ugandan prospective cohort study,
Mutabazi-Mwesigire (2015) reported that female gender was associated with lower MHS
scores after adjustment [26]. In a cohort study also conducted in Uganda, Weiser (2012)
reported lower PHS score in women treated at a regional referral hospital [27]. Although no
specific explanation for these negative associations was reported in both studies, previous
research has suggested that lower QoL measured in women may be attributable to gender
differences in the reporting of psychological illnesses and somatic complaints [29,30].
Unsurprisingly, food insecurity was negatively associated with mental and physical
health. This is predictable in sub-Saharan Africa, where it continues to be a daily concern for
millions of people. One of the reasons explaining this association is the exacerbation of side
effects caused by the lack of food to accompany ART [31]. This directly impacts the health
outcomes and QoL of HIV patients who skip meals to afford their medication or do not
adhere to treatment because of the lack of food. Our findings are similar to results from
previous research in Ghana, Ethiopia and Uganda, where decreased QoL scores where
measured in patients reporting food insecurity [32-34]. In a cross-sectional study of 664 HIV
patients in Ethiopia, Mekuria (2015) specifically found that being able to obtain food with
sufficient nutritional value was key to increasing physical, psychological, social,
independence and environmental domains of QoL scores [33].
Our study had several strengths. We investigated QoL in a region not well studied
before and we provided insight on the QoL of adult PLHIV receiving ART in a patientoriented community clinic in Lomé. Moreover, we included a wide range of independent
variables in our analysis and assessed pertinent factors such as food insecurity and treatment76

related side effects. Also, using a linear regression with model selection allowed us to control
for confounding variables and select the variables best explaining the relationship between
physical and mental domains of QoL and several risk or protective factors. This study also
had limitations. The cross-sectional design limited our ability to establish a temporal
relationship between the dependent and independent variables. Additionally, although the use
of trained investigators instead of a self-administration approach to administer the MOS-HIV
questionnaire was necessary due the lack of reading ability for several patients, it may have
caused patients to inflate the positivity of their responses. As a result, QoL scores may have
been overestimated due to social desirability bias. Also, our study was conducted in one
community clinic in Lomé therefore our findings may not be generalizable to different
settings.
Overall, the social support provided by the clinic in addition to treatment is likely to
positively impact patients’ QoL and overall wellbeing [11]. Future research should be
extended to pediatric populations and potentially focus on comparing treatment satisfaction
in patients treated in public hospitals and those treated in community health clinics.
Conclusion
This study suggests that PLHIV treated at a patient-oriented community health clinic
in Lomé, Togo, had high physical health summary scores and moderately high mental health
summary scores, as assessed by the MOS-HIV health survey. Age, gender, education, food
security, treatment-related side effects and self-evaluated health status were significantly
associated with physical and mental health summary scores in this population. Sustained care
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in a community health clinic, where the factors influencing QoL are also addressed during
patient management, is key to ensure long-term viral suppression in PLHIV in Togo.
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Abstract
Qualitative assessments of the quality of life (QoL) of HIV patients treated with
antiretroviral therapy (ART) in western and central Africa are few in comparison to those in
other parts of sub-Saharan Africa, Europe, and North America. Yet, valuable information can
be discovered from patients’ individual experiences that can identify new variables not
included in typical surveys. We interviewed 12 HIV patients receiving long-term ART at
Espoir Vie Togo, a community health clinic providing social support, during July and August
2019. All interviews were recorded, transcribed, and analyzed using a thematic analysis.
Participants described good QoL as being in good health and being physically and mentally
functional. Family, social and community support, the presence of a supporting individual,
being on ART and food security were the main factors influencing QoL. In this cohort,
participants experienced difficulties accepting their positive status, and often experienced
perceived and enacted stigma. Ultimately, the positive effects of long-term care led
participants to become more “responsible” and better cope with their disease.
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Introduction
The prevalence of people living with HIV (PLHIV) in sub-Saharan Africa has risen
steadily in the last decade because of the increased access to life-saving antiretroviral therapy
(ART) (1). Although the HIV/AIDS epidemic has declined since its peak in 2005, HIV
prevalence in sub-Saharan Africa is still the highest in the world, with an estimated 25.6
million PLHIV at the end of 2018 (2). In Togo, a small West African nation with a
population of 7.9 million as of 2018, approximately 65,000 people received ART out of an
estimated 110,000 PLHIV (3). The country made considerable progress towards limiting the
spread of the epidemic, as shown by key indicators: in 2018, approximately 66% PLHIV
knew their status, 89% of them received ART and 79% of the 21,000 PLHIV under ART
who were able to have their viral load measured had viral suppression (4,5,6). These rates
place Togo among the countries closest to reaching the 90-90-90 targets in sub-Saharan
Africa, notably because of its small size, and because the epidemic has historically been
moderate compared to more affected countries such as South Africa or Uganda.
Nevertheless, the country-wide measures taken by health authorities to control the epidemic
have been relatively successful so far (3,4). At the patient level, these milestones mean that
HIV infection is no longer a death sentence and it is possible for newly infected individuals
who initiate ART early and adhere to treatment to live a long and productive life (7). In fact,
HIV has shifted from a fatal infection to a chronic disease when antiretrovirals became
widely available in Togo after the “3 by 5” initiative was launched in 2003 to provide 3
million doses of ART to people living with HIV (PLHIV) in low- and middle-income
countries by the end of 2005 (8). One of the challenges in HIV management today despite the
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increased access to ART is to ensure patients are sufficiently empowered to adequately cope
with their disease. Ideally, HIV patients should be able to maintain high rates of adherence to
be virally suppressed over time and no longer transmit the disease (9). To this end, quality of
life (QoL) has emerged as a significant follow-up outcome aiming at mitigating the
challenges associated with lifelong treatment such as sustained adherence and economic
difficulties (10).
Several studies have investigated QoL among PLHIV across sub-Saharan Africa to
determine the factors associated with QoL and to capture individual life experiences
(11,12,13). Specifically, several public health studies in western and central Africa have
taken a qualitative approach and given voice to HIV patients to deeply understand their
experience (14-17). In Cameroon, Alomepe (2016) interviewed women living with HIV and
described the challenges they faced. The emerging themes included the trauma of
discovering one’s status, the difficulties of living with HIV, the lack of resource and support,
and stigma (14). In addition to their illness, these issues affected their ability to perform their
central role in their family. In a qualitive study conducted in Ethiopia, Alemayehu (2017)
described the main aspects affecting QoL in visceral leishmaniasis and HIV coinfected
males: liveability of the environment, utility of life, life ability of a person and appreciation
of life (16). The study highlighted the multidimensional nature of QoL and the importance of
starting specific programs to address these issues. In another qualitative study of newly
infected patients conducted in Nigeria, Ogbuji (2010) found that psychological factors such
as sadness, hopelessness, anxiety and fear were widely reported by PLHIV as negative
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factors influencing QoL, although certain life adjustments and psychological support allowed
to better cope with the disease (17).
Among factors affecting the QoL of PLHIV, stigma is frequently cited as one of the
most enduring, despite general knowledge of the positive effects of ART on curbing the HIV
epidemic (18). Several types of stigma have been described, including enacted and perceived
stigma, both strongly acting as barriers to coping with the disease. Enacted stigma includes
acts of discrimination and negative treatment from external sources towards PLHIV.
Perceived stigma is the awareness and fear of being perceived negatively in society because
of one’s HIV status, causing the avoidance of social experiences and opportunities (18).
Previous research has indicated that perceived stigma has a negative impact on overall QoL,
but it may vary according individual contexts and different settings (19).
The World Health Organization describes QoL as an “individual perception”, and
individual experiences vary according to social, cultural and religious contexts. Receiving
sustained treatment also strongly influence individual experiences because of its strong and
durable positive effects on the mental and physical health of HIV patients (20,21). There is
more to learn about subjective factors associated with QoL shaped by personal, cultural or
social experiences that are unique to each patient, especially in the context of a community
health clinic, where patients are long-term ART recipients and experience strong social
support in addition to receiving treatment (22). In such a population, certain underlying
factors other than traditional socio-demographic and treatment-related factors significantly
influence patients’ QoL and general wellbeing. Therefore, the objective of this study was to
understand patients’ definitions of QoL, identify and gain additional knowledge on
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underlying and undiscovered indicators of quality of life, and better understand the life
experiences of HIV patients receiving long-term ART in a community health clinic in Togo.

Methods
Study Setting and Population
We conducted 12 semi-structured interviews of six female and six male patients
receiving long-term ART in July and August 2019 at Espoir Vie Togo (EVT), a community
health clinic and non-governmental organization treating and providing social support to HIV
patients in Togo. EVT currently manages approximately 3,500 patients and has clinics in
Lomé, the capital, and in Aného and Sokodé (22). Consecutive patients of the outpatient
clinic in Lomé were asked to participate in the study prior to their doctor visit and
participants received a 500 CFA (~ US $0.85) token as reimbursement for travel expenses.
Eligibility criteria to participate in the study were being 18 years or older, having a confirmed
HIV diagnosis and currently receiving ART for more than six months.
Data Collection
Face-to-face individual interviews were designed to give participants the opportunity
to discuss their perceptions of QoL and factors influencing their QoL. The primary
investigator (HS), assisted by a clinical psychologist with qualitative interview experience
(JMAA), conducted the interviews, which took place in a private consultation room. All
interviews were held in French, the official language and first language of most participants,
and lasted approximately 15 minutes. The interviews were recorded on a digital audio
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recorder. Written notes were also taken by the study investigator during the discussion. All
participants agreed to be recorded.
Prior to starting the interview, the following characteristics were collected from the
patient’s medical record: age, CD4 count, treatment duration, line of treatment, and
adherence. Gender, education level, employment, marital status, HIV status disclosure, food
insecurity and social or family support were self-reported. Adherence was defined as not
missing two consecutive doctor’s appointments and taking all of one’s pills in the week
preceding an appointment. Food insecurity was measured with Kleinman’s validated oneitem screening question (23).
Based on an interview guide developed specifically for this study, the study
investigator used a series of open-ended questions to encourage participants to share their
experience and describe how their lives were affected by HIV (interview guide available
from HS). The questions prompted participants to share their definition of QoL and describe
their perceived determinants of QoL. The discussion was kept relatively informal to let
participants engage in a conversation rather than in a question-answer session. This approach
also encouraged participants to give honest answers.
Data Analysis
All interviews were transcribed and translated from French to English. We used
pseudonyms throughout the study when quoting participants to maintain anonymity. Data
analysis was performed using OpenCode version 4.0 (24). Data were analyzed following a
thematic analysis. English transcripts were read multiple times to become familiar with the
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content. The primary investigator (HS) used an open coding approach to capture the
participants’ perception of QoL. After coding several transcripts, a set of codes was defined
and subsequently used for similar recurring concepts. Additional codes were incorporated
into the analytical framework as they were identified in subsequent transcripts. Several
themes emerged and were examined at the latent level: the investigator sought to detect
underlying ideas and concepts by analyzing patients’ words beyond what was said verbatim
during the interviews. All themes were reviewed by an experience researcher who did not
take part in the interviews (SM).

Ethical Approval
Ethical approval for this study was obtained from the Comité de Bioéthique pour la
Recherche en Santé (031/2019/CBRS) in Togo, and from the University of Texas Health
Science Center at Houston’s Committee for the Protection of Human Subjects (HSC-SPH19-0357) in the United States. Prior to study inclusion, all participants were read a script
describing the study before providing oral informed consent.
Results
Twelve participants (6 women, 6 men) were enrolled in the study. All patients who
were approached for study participation agreed to participate. The mean age was 32.6 years,
and the majority had at least a secondary level of education and were single (Table 1). The
mean duration of treatment was 96 months, and six participants were on their second line of
treatment. All participants were adhering to treatment according to the study definition.
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Definition of a good quality of life
Most participants described QoL as a combination of intertwined factors that resulted
in a good QoL when all were functioning well. David told us: “To have a good quality of life
is to be able to do any activity that would be expected of you. In other words, having the
power to go about your business as usual without any constraints” (interview 1, David, 23
years old). When specific features were discussed, “being in good health” was repeatedly
mentioned as the main, if not the sole definition. Good QoL was also defined as overall
wellbeing and being functional at the physical and mental levels. Justine mentioned that a
good QoL was conditional on taking ART, thus acknowledging the importance of the role
played by medications in improving symptoms and overall wellbeing (interview 3, Justine,
18 years old). Kossi shared a different perspective on the definition of QoL that was outside
of the usual scales: in his opinion, good QoL was about being free of problems, which
negatively affected his mental health and prevented him from focusing on the important
things in his life (interview 10, Kossi, 19 years old).
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Table 9. Baseline Characteristics of 12 HIV Patients at Espoir Vie Togo.
Characteristic
N (%) or Mean (SD)
Gender
Female
Male
Age (years)
Education
Primary
Secondary
University
Employment
Unemployed
Employed
Marital Status
Single
Married/Cohabiting
Divorced/Separated

6 (50)
6 (50)
32.6 (14.8)
1 (8.3)
9 (75)
2 (16.7)
7 (58.3)
5 (41.7)
8 (66.7)
2 (16.7)
2 (16.7)

HIV Status Disclosure
Food Insecurity
Line of Treatment
First
First Substituted
Second

11 (91.7)
8 (66.7)

Adherence
Family or Social Support
Treatment Duration (months) (n=11)
CD4 (cells/µL) (n=11)

12 (100)
9 (75)
96 (84.1)
613.9 (347.9)

3 (30)
1 (10)
6 (60)

Determinants of QoL
Living with HIV is challenging and imposes many constraints but for patients
receiving long-term ART, general health improvements related to medication intake allow
patients to focus more on their quality of life, and less on their health. At EVT, patients
receive free treatment and are followed by psychologists, and this relieves part of the
concerns related to being able to afford the therapy. Patients described the factors that
improved or deteriorated their quality of life. For example, the support received by family
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and friends helped several patients cope with their disease. David described the positive
influence he received from some members of his family after discovering he was HIV
positive: “In my family, only my brothers and my sister knew my status. They were always
watching after me, they always gave me advice. When I tried to break certain rules, they
helped me get back on track.” Additionally, the medical and social support provided by EVT
and its community played an important part in successfully managing the disease, as Grace
stated: “I pray every day for EVT to continue their work because they work so well. They
give us advice, they give us food” (interview 2, Grace, 44 years old).
Sometimes, it was a specific person who played a key role in a patient’s ability to
successfully cope with the disease. Friends and family members are often cited as supporting
groups, but it could be a single individual who made a difference in this patient’s life. Leila
said: “I have a friend (not a boyfriend), who knew my illness from the beginning. He is the
first person I told. He really supported me. When he talks to me, I forget that I am sick”
(interview 5, Leila, 40 years old).
The benefits of taking ART was mentioned during several interviews. Because our
population was long-term ART recipients, patients were maintained on stable regimens and
they have had the opportunity to discuss and address potential side effects with the doctor.
Kossi said: “Before taking ART, I got sick very often, but now, I only get sick once or twice
in a three-month period.” Referring to his height, he added: “I even grew taller.” (interview
10, Kossi, 19 years old).
Food insecurity and the toxicity associated with taking ART without a meal were significant
problems for low income patients and young adults. Many patients were aware of the
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possible consequences on treatment adherence. Linda reported: “I know that taking the
treatment keeps me in good health. But taking the treatment means I must eat too, and if I
don’t, there will be side effects. So sometimes, if I know I won’t eat, I won’t take my
medications because of the side effects” (interview 4, Linda, 23 years old).
Participants mainly described factors that contributed to improve their QoL such as family or
social support and being under life-saving treatment. Because patients were receiving
treatment for over 6 months and were on good health, they did not spontaneously think of
negative factors, however, risk factors negatively associated with QoL were also discussed.
Stigma is an enduring concern for PLHIV and it was brought up often enough during the
interviews to emerge as a theme.

Experiencing enacted and perceived stigma
Study participants from both genders clearly understood the negative toll HIV had on
their lives and they were able to easily communicate on their experiences. Several
participants stated that they were negatively affected by the lack of awareness in the general
population and they complained they were systematically judged and stigmatized although
they were receiving ART and their disease was perfectly under control. Enacted stigma refers
to acts of discrimination and negative treatment from external sources towards PLHIV. It was
usually experienced outside of the close circle of friends or family knowing the participant’s
HIV status. Perceived stigma originated within participants and they felt it when
misinformation about HIV was circulated and they feared they would be treated negatively if
their status was disclosed. Ousmane said: “Here’s the difference between you and an HIV
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negative person: sometimes, you cannot even stay among your friends because you may not
feel well and be afraid people discover you have HIV” (interview 12, Ousmane, 50 years
old).
Like Ousmane, several participants indicated they had to hide their status to avoid stigma,
discriminations or insults. Moreover, some participants said they were ashamed of their
disease. Participants acknowledged it was harder to make platonic or romantic connections
because of their status and perceived stigma, and their fear of rejection and enacted stigma.
For example, Joel revealed: “I’m afraid sometimes to have romantic relationships, while an
HIV negative person can live his life fully as he wants.” (interview 11, Joel, 18 years old).
The lack of sexual partner was also brought up by Grace, who knew her status deteriorated
her intimacy: “since I’ve had HIV, I do not make love anymore and it bothers me. When I
find a partner, he tells me he does not want to use a condom so I have to refuse because I do
not want that” (interview 2, Grace, 44 years old).
Despite being under long-term treatment and having their disease under control, many
participants are paralyzed by perceived stigma and fear the upsetting effects of enacted
stigma. Some participants admitted they had lost friends or family because perceived and
enacted stigma led them to avoid situations in which they could be shamed, some chose to
stay away from people and preferred to be solitary. The desire to avoid stigma was so strong
it led some to being abstinent, which some also described as being more “responsible” as we
see in the next theme.
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Becoming more “responsible”
Being infected with HIV unexpectedly uncovered optimistic reactions and feelings of
responsibility among several patients over time. In fact, some participants mentioned that
they developed an increase in responsibility because of their disease, while others
experienced a positive change in their behavior after being diagnosed and starting ART.
Edem reflected on his past life and offered a powerful statement:
Before my diagnosis, I lived a life not quite as one wishes, I had unprotected
sex, I had multiple partners, I drank a lot of alcohol, and I smoked too. After
the diagnosis, I stopped having unprotected sex and being with multiple
partners. I no longer smoke or drink. I would tell a newly infected person to
get tested, to follow the advice of doctors, to take the medication every day
and at the times indicated, to eat well, and to protect himself during each
intercourse.” (interview 9, Edem, 59 years old).
This radical change in behavior was not infrequent in our population. At many occasions,
being responsible vis-à-vis taking medications, and being responsible by adopting a healthier
behavior was how participants chose to deal with their disease after several months under
treatment. Speaking about the disease, Ousmane said: “You have to live with it. Live your
life! Follow the advice of doctors, take your medicine in time, and you'll be happy like any
other man. There are people damaging their own health because they tell themselves "I'm a
sick person” (interview 12, Ousmane, 50 years old). It is likely that the patients in our study
who become responsible and adopted positive attitudes were only able to do so because their
disease were well-controlled and no longer represented the main concern in their daily lives.
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Grief and difficulties of status acceptance
Although maintaining good physical health was no longer a barrier for performing
daily activities for participants in our sample of long-term care receivers, we collected a few
testimonials that reflected persistent emotional distress and a feeling of grief for a way of
living that was lost. In fact, Ousmane confessed that the hardest thing for him was the quest
he pursued after discovering his positive status. He absolutely wanted to know how he
became infected and after several months of unsuccessful attempts to discover what
happened, he found peace only when he decided to let go and move on:
At first, I tried to find out where it came from, but I could not find the answer.
People warned me it could drive me crazy to absolutely want to know how it
happened. Later, I understood it was true. I was devastated for a while, but I
knew I had to give up to move forward, so this is my spirit now. (interview
12, Ousmane, 50 years old).
This feeling of grief was similar to what other patients experienced, as they struggled to
accept and live with their newly discovered positive status. Kossi believed that one’s own
perception of the disease determined their QoL, whether it was good or bad, so it was
preferable to accept one’s condition and look forward: “often we, HIV patients, demean
ourselves, and society does nothing but repeat the way we treat ourselves” (interview 10,
Kossi, 19 years old). Marie also experienced difficulties when she discovered her status and
saw her life change abruptly. She recalled: “I did not go out anymore. I was afraid to be sick
so I stayed at home. I was crying and I did not have any friends anymore” (interview 6,
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Marie, 48 years old). These experiences show the emotional difficulties of discovering one’s
positive status, and they suggest many participants have personal struggles before finding
much needed support, sometimes through family and loyal friends, but often in community
clinics like EVT.
Discussion
We investigated the life experiences and perceptions of QoL of twelve HIV patients
receiving long-term ART in a community health clinic in Lomé, Togo. Participants defined
good QoL as being in good health and being functional at a physical and mental level. The
main factors influencing QoL were family, social and community support, the presence of a
supporting individual, being on ART and food insecurity. The positive effects of long-term
care often transformed patients and allowed some of them to become responsible vis-à-vis
their disease. However, prior to developing positive attitudes over time, participants first
experienced personal difficulties related to their newly discovered positive status, and they
continue to face stigma, even after overcoming their personal struggles.
Overall, our findings diverged from Ogbuji’s (2010), who reported predominantly
negative feelings and experiences in a qualitative study of newly diagnosed HIV patients in
Nigeria (17). In Ogbuji’s study, many participants reported that HIV was a punishment for
their previous careless lifestyle, others were overwhelmed by discrimination, stigmatization
and feelings of embarrassment. A few patients went as far as contemplating suicide. We note
that Ogbuji’s research involved newly diagnosed patients while our study population
included long-term ART recipients. Although it is difficult to make meaningful comparisons,
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our findings suggest that life experiences and QoL are likely to improve over time because of
the positive effects of sustained antiretroviral treatment. Hence, Ogbuji’s population
illustrated patients’ overall health impairment at the early stage of the disease whereas our
population exemplified a possible positive evolution after several months of treatment. The
better health outcomes and positive transformation of patients over time in our sample can
also be attributed to the overall positive impact of EVT’s disease management strategy
during patient follow up. In fact, the clinic has a very strong social component and its team of
psychologists support patients in their daily needs (22).
Our study confirms previous research suggesting experiences of enacted and
perceived stigma are main concerns for patients and negatively affect QoL and overall
wellbeing among PLHIV. In a mixed sample of patients, health personnel and care providers,
Adedimeji (2010) reported that perceived stigma contributed to the non-disclosure of one’s
status (15). Patients preferred limiting the disclosure of status to their close friends and
family, and they sought treatment in places where they could remain anonymous. Women
were disproportionally affected, as described by Alomepe (2016). They faced enacted stigma
from their communities and even their families, because of the false perception that women
with HIV engaged in immoral activities (14). In addition, they felt powerless as they lost
their preponderant role as a pillar of society, as it is often the case for women in the subSaharan African culture. Similar experiences with perceived stigma were described in our
study because regardless of the setting, HIV patients felt powerless in front of an issue
coming from external sources and driven by negative perception of the disease. Adedimeji’s
study was conducted 10 years ago, when ART was not as generalized in sub-Saharan Africa
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as it is today. In the early 2010s, the general population still negatively perceived people
living with HIV due to the lack of awareness, and it seems this trend is perduring today
although it is unclear to what extent.
Our findings are in accordance with those reported in Uganda by MutabaziMwesigire (2014), who conducted in-depth interviews at three and six months follow up with
patients in an urban clinic as part of a prospective cohort study (25). The author reported that
happiness was a strong indicator of good QoL and it was supported by good social networks
and family. Happiness, and more generally, appreciation of life, reflected the positive attitude
HIV patients can adopt to face their condition and improve their QoL, especially when they
have been treated with ART for a long period of time. Although happiness was not
specifically named in our study, many factors mentioned by our interviewees were proxies,
specifically mental wellbeing.
Several determinants of QoL described in this study were seldom investigated in
previous research. Feelings of responsibility and the lack of sexual intercourse or the lack of
sexual partner are often overlooked when considering HIV patients’ overall wellbeing, yet,
those features were found to hinder several participants’ ability to feel whole. Additionally,
family and social support are often cited as significant factors positively affecting QoL, but
we noted that only one person can sometimes make a difference in a patient’s life and
provide sufficient support when needed, especially if the patient and the confident were close
prior to the disease, or if the person in need prefers to not disclose their status to other people
and remain discreet.
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It was not surprising that food insecurity was discussed by interviewees in our study,
considering that it continues to be a major issue in developing countries. In Togo, an
estimated 69% of households were living below the poverty line in 2015 (26). Food
insecurity is thought to exacerbate ART-related side effects, and its effects on decreasing
adherence to treatment in resource-limited settings have been previously demonstrated
(27,28). Musumari (2013) reported on the negative impact of food insecurity on adherence
among patients on ART, on ART-retreatment and those ultimately lost to follow-up. This
issue was significant enough for UNAIDS to recommend stakeholders to associate food
assistance programs to ART programs (29).
Our study had several strengths. All participants who were approached for study
participation agreed to participate, limiting selection bias. Also, because all participants
agreed to be recorded, the content of the interviews was accurately transcribed, and it
allowed the analysis to be based on complete and detailed material, supported by written
notes. This study also had limitations. We interviewed patients who were followed up in a
community health clinic providing social support, and we anticipated their overall wellbeing
and QoL to be better than patients cared for in public hospitals. Also, the mean treatment
duration of 96 months in our population indicates that our results are not applicable to newlydiagnosed HIV patients. Finally, our sessions lasted approximately 15 minutes, which was
relatively brief to conduct in-depth interviews.
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Conclusion
This study assessed HIV patients receiving long-term care at a community health
clinic with a strong social support component in Lomé, Togo, to better understand patients’
definitions of QoL, how HIV impacted their lives, and define the factors influencing QoL
from their perspective. Despite the early difficulties and enacted and perceived stigma
experienced by HIV patients, ART and other sociodemographic factors can improve their
overall wellbeing and QoL over time.
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CONCLUSION

We carried out this dissertation to synthesize current knowledge on the factors
associated with QoL among ART-treated HIV patients in sub-Saharan Africa, and identify
novel factors associated with QoL to provide foundations for the optimization of HIV care,
based on the sociodemographic, clinical, behavioral, and psychological determinants of QoL.
Our long-term goal was to provide robust evidence to help improve the overall management
of people living with HIV.
This dissertation confirmed the significant impact of certain factors associated with
QoL such as ART, age, education level, gender, CD4 count, and mental health, but also
encountered pertinent factors such as food insecurity, tuberculosis, and the lack of sexual
partner. We highlighted several themes patients experience when coping with their disease
such as experiencing enacted and perceived stigma, becoming more “responsible”, and
facing difficulties accepting HIV status.
One of the strengths of this dissertation was the focus on the sub-Saharan African
experience, a severely affected region, where essential summary data on the factors
associated with QoL was lacking. We chose to support our research with robust evidence
collected from a systematic review and direct our efforts towards discovering new
information collected in real-world settings. On the other hand, this dissertation was limited
by its lack of generalizability. In fact, Togolese HIV patients treated at a community health
clinic are not representative of PLHIV in sub-Saharan Africa. This dissertation was also
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limited by the small number of patients’ testimonies in our interviews which limited our
ability to gain further insight on the life experience of HIV patients in this setting.
Nevertheless, we are confident that this dissertation addressed current gaps in
knowledge and opened the door to future research. We reported that the QoL scores of HIV
patients treated at a community health clinic in Togo were relatively higher compared to
equivalent studies in Kenya and Rwanda. Future research may be conducted to attempt a
comparative analysis evaluating the QoL and treatment satisfaction of patients treated at
Espoir Vie Togo, or other non-governmental organizations, versus patients treated at a public
healthcare facility, which lack the social support component provided at Espoir Vie Togo and
similar facilities. Furthermore, additional research may be conducted on certain factors
influencing QoL reported in our interviews to assess whether they are quantitatively
associated.
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APPENDICES

Appendix A: Ovid Medline Search Strategy

1. HIV-2/ or HIV/ or HIV Seropositivity/ or HIV-1/
2. hiv infections/ or acquired immunodeficiency syndrome/
3. (hiv or aids).ti,ab,kw.
4. 1 or 2 or 3
5. "Quality of Life"/
6. ("Quality of Life" or QOL or HRQoL or "Health-related quality of life").ti,ab,kw."
7. 5 or 6
8. africa/ or "africa south of the sahara"/ or africa, central/ or cameroon/ or central african
republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or
gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/
or somalia/ or south sudan/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or
botswana/ or lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/
or zambia/ or zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote
d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/
or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/
9. (Angola or benin or botswana or burkina faso or burundi or cameroon or cape verde or
"central african republic" or chad or congo or "cote d'ivoire" or djibouti or eritrea or ethiopia
or gabon or gambia or ghana or guinea or kenya or lesotho or liberia or malawi or mali or
mauritania or mozambique or namibia or niger or nigeria or rwanda or senegal or "sierra
leone" or somalia or saharan or sudan or swaziland or tanzania or togo or uganda or zambia
or Zimbabwe).ti,ab,kw.
10. 8 or 9
11. 4 and 7 and 10
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Appendix B: PubMed Search Strategy

1. (HIV-2[mesh] or HIV[mesh] or HIV Seropositivity[mesh] or HIV-1[mesh]) OR (hiv
infections[mesh] or acquired immunodeficiency syndrome[mesh]) OR (hiv[tiab] or
aids[tiab])
2. ("Quality of Life"[mesh]) OR ("Quality of Life"[tiab] or QOL[tiab] or HRQoL[tiab] or
"Health-related quality of life"[tiab])
3. (africa[mesh] or "africa south of the sahara"[mesh] or africa, central[mesh] or
cameroon[mesh] or central african republic[mesh] or chad[mesh] or congo[mesh] or
"democratic republic of the congo"[mesh] or equatorial guinea[mesh] or gabon[mesh] or
africa, eastern[mesh] or burundi[mesh] or djibouti[mesh] or eritrea[mesh] or ethiopia[mesh]
or kenya[mesh] or rwanda[mesh] or somalia[mesh] or south sudan[mesh] or sudan[mesh] or
tanzania[mesh] or uganda[mesh] or africa, southern[mesh] or angola[mesh] or
botswana[mesh] or lesotho[mesh] or malawi[mesh] or mozambique[mesh] or namibia[mesh]
or south africa[mesh] or swaziland[mesh] or zambia[mesh] or zimbabwe[mesh] or africa,
western[mesh] or benin[mesh] or burkina faso[mesh] or cape verde[mesh] or cote
d'ivoire[mesh] or gambia[mesh] or ghana[mesh] or guinea[mesh] or guinea-bissau[mesh] or
liberia[mesh] or mali[mesh] or mauritania[mesh] or niger[mesh] or nigeria[mesh] or
senegal[mesh] or sierra leone[mesh] or togo[mesh]) OR (Angola[tiab] or benin[tiab] or
botswana[tiab] or burkina faso[tiab] or burundi[tiab] or cameroon[tiab] or "cape verde"[tiab]
or "central african republic"[tiab] or chad[tiab] or congo[tiab] or "cote d'ivoire"[tiab] or
djibouti[tiab] or eritrea[tiab] or ethiopia[tiab] or gabon[tiab] or gambia[tiab] or ghana[tiab] or
guinea[tiab] or kenya[tiab] or lesotho[tiab] or liberia[tiab] or malawi[tiab] or mali[tiab] or
mauritania[tiab] or mozambique[tiab] or namibia[tiab] or niger[tiab] or nigeria[tiab] or
rwanda[tiab] or senegal[tiab] or "sierra leone"[tiab] or somalia[tiab] or saharan[tiab] or
sudan[tiab] or swaziland[tiab] or tanzania[tiab] or togo[tiab] or uganda[tiab] or zambia[tiab]
or Zimbabwe[tiab])
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Appendix C: Embase Search Strategy

1. (HIV-2 or HIV or HIV Seropositivity or HIV-1) OR (hiv infections or acquired
immunodeficiency syndrome) OR hiv.ab,kf,ti. OR aids.ab,kf,ti.
2. Quality of Life.ab,kf,ti. OR QOL or HRQoL OR health-related quality of life
3. ‘sub-saharan africa‘ or ‘africa south of the sahara’ or africa, central or cameroon or
‘central african republic’ or chad or congo or ‘democratic republic of the congo’ or
‘equatorial guinea’ or gabon or ‘africa, eastern’ or burundi or djibouti or eritrea or ethiopia or
kenya or rwanda or somalia or south sudan or sudan or tanzania or uganda or ‘africa,
southern’ or angola or botswana or lesotho or malawi or mozambique or namibia or south
africa or swaziland or zambia or zimbabwe or ‘africa, western’ or benin or burkina faso or
cape verde or cote d ivoire or gambia or ghana or guinea or guinea-bissau or liberia or mali
or mauritania or niger or nigeria or senegal or ‘sierra leone’ or togo
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Appendix D: PsycINFO Search Strategy

1. HIV-2/ or HIV/ or HIV Seropositivity/ or HIV-1/
2. hiv infections/ or acquired immunodeficiency syndrome/
3. (hiv or aids).ti,ab
4. 1 or 2 or 3
5. "Quality of Life"/
6. ("Quality of Life" or QOL or HRQoL or "Health-related quality of life").ti,ab
7. 5 or 6
8. africa/ or "africa south of the sahara"/ or africa, central/ or cameroon/ or central african
republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or
gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/
or somalia/ or south sudan/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or
botswana/ or lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/
or zambia/ or zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote
d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/
or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/
9. (Angola or benin or botswana or "burkina faso" or burundi or cameroon or cape verde or
"central african republic" or chad or congo or "cote d'ivoire" or djibouti or eritrea or ethiopia
or gabon or gambia or ghana or guinea or kenya or lesotho or liberia or malawi or mali or
mauritania or mozambique or namibia or niger or nigeria or rwanda or senegal or "sierra
leone" or somalia or saharan or sudan or swaziland or tanzania or togo or uganda or zambia
or zimbabwe).ti,ab
10. 8 or 9
11. 4 and 7 and 10
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Appendix E: French Version of the Verbal Consent Script
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Appendix F: Espoir Vie Togo’s Patient Routine Visit Card (Page 1 [Left] and 2 [Right])
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Appendix G: English Version of the MOS-HIV

116

117

118

119

120

121

Appendix H: French Version of the MOS-HIV
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Appendix I: Espoir Vie Togo Support Letter
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Appendix J: Outcome Letter from the Comité de Bioéthique pour la Recherche en Santé
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Appendix K: Outcome Letter from UTHealth’s Committee for the Protection of Human
Subjects (CPHS)

133

Appendix L: Outcome Letter from UTHealth’s CPHS – Protocol Change – Travel
Reimbursement
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Appendix M: Outcome Letter UTHealth’s CPHS – Protocol Change – Sample Size Increase
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